1714 articles by Jacob Bell

• An Arch-backed biotech raises $53M to fight neurodegeneration

  Dec. 4, 2025

• UniQure slides further on outlook for Huntington’s gene therapy

  Dec. 4, 2025

• After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

  Dec. 3, 2025

• The ‘clever’ tool increasingly getting bigger biotech deals signed

  Dec. 2, 2025

• Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies

  Nov. 24, 2025

• A brain biotech’s top drug fails against MS

  Nov. 21, 2025

• Merck’s blockbuster-to-be cardiovascular drug scores in another heart study

  Nov. 18, 2025

• To Wall Street, a new bidding war puts Alkermes in a tough spot

  Nov. 14, 2025

• Neurocrine chalks up a depression drug failure

  Nov. 10, 2025

• Roche’s MS tablet scores in late-stage studies

  Nov. 10, 2025

• Knocked back by the FDA, Biohaven turns to major cost cuts

  Nov. 5, 2025

• Vertex’s new pain, blood disorder drugs miss Wall Street expectations

  Nov. 4, 2025

• UniQure dives after FDA’s ‘very surprising’ reversal on Huntington’s gene therapy

  Nov. 3, 2025

• Roche taps an AI specialist to craft new brain drugs

  Nov. 3, 2025

• Lilly quietly cuts a pain drug from its pipeline

  Oct. 31, 2025

• Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win

  Oct. 30, 2025

• Biogen licenses a possible immune drug from OrbiMed-backed biotech

  Oct. 24, 2025

• Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal

  Oct. 24, 2025

• Alkermes expands sleep portfolio with acquisition worth up to $2.1B

  Oct. 22, 2025

• Alto shares double on plans to speed depression drug’s development

  Oct. 20, 2025

• Exelixis shares dip on colorectal cancer data

  Oct. 20, 2025

• A longshot bet on a tremor drug pays off

  Oct. 16, 2025

• A regenerative therapy for hair loss attracts a mega-fundraising round

  Oct. 15, 2025

• Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

  Oct. 12, 2025

• Venture firms pour $101M into a biotech using the brain to fix the immune system

  Oct. 8, 2025

• A new biotech aims to get RNA drugs into the brain

  Oct. 1, 2025

• Cancer patients are living longer than ever. Pain drugmakers haven’t kept up.

  Sept. 25, 2025

• A new class of sleep drugs draws Wall Street’s attention

  Sept. 8, 2025

• Biohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval

  Sept. 3, 2025

• Novartis thinks Arrowhead brain drug can succeed where others couldn’t

  Sept. 2, 2025

• AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug

  Aug. 25, 2025

• Reunion’s psychedelic drug headed to late-stage testing

  Aug. 18, 2025

• A brain biotech slumps even with ‘best case’ seizure data

  Aug. 4, 2025

• In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A

  July 31, 2025

• Atai backs away from schizophrenia drug after trial failure

  July 28, 2025

• In reversal, European regulators take positive view on Lilly Alzheimer’s drug

  July 25, 2025

• Alkermes narcolepsy drug headed for late-stage testing

  July 21, 2025

• Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline

  July 2, 2025

• Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment

  July 1, 2025

• Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street

  June 26, 2025

• Compass’ big psychedelic study doesn’t impress investors

  June 23, 2025

• NewAmsterdam says cholesterol drug may also combat Alzheimer’s

  June 9, 2025

• Biotech funding plummets as Trump policies unnerve investors: Jefferies

  June 4, 2025

• Sanofi to acquire Blueprint for up to $9.5B

  June 2, 2025

• Lilly to buy pain drug developer SiteOne, challenging Vertex

  May 27, 2025

• Sanofi gains experimental Alzheimer’s drug through Vigil buyout

  May 22, 2025

• BioMarin to buy rare disease drugmaker Inozyme for $270M

  May 16, 2025

• FDA delays approval decision for Biohaven rare disease drug

  May 15, 2025

• Galapagos backtracks on planned split

  May 13, 2025

• Viatris’ new form of old pain drug scores in large trials

  May 8, 2025

• Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously

  May 6, 2025

• AstraZeneca quietly exits neuroscience

  May 1, 2025

• Biohaven stock slides on withdrawal of European marketing application

  April 25, 2025

• Bristol Myers says schizophrenia drug launch ‘off to a solid start’

  April 24, 2025

• Bristol Myers’ prized schizophrenia drug stumbles in testing

  April 23, 2025

• Former Neumora CEO to lead Galapagos spinout

  April 22, 2025

• New research kindles excitement around stem cell therapies for Parkinson’s

  April 16, 2025

• GSK targets neurodegenerative diseases with latest licensing deal

  April 7, 2025

• M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals

  April 4, 2025

• FDA approves first-of-its-kind RNA drug for hemophilia

  March 28, 2025

• Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen

  March 28, 2025

• Biogen plots new global headquarters in Kendall Square

  March 24, 2025

• Novartis builds case for new SMA gene therapy

  March 20, 2025

• Latigo raises $150M to get non-opioid pain drugs through key tests

  March 17, 2025

• MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

  March 13, 2025

• J&J scraps depression testing for potential blockbuster drug

  March 7, 2025

• Vertex’s new pain drug gets first coverage nod from major insurer

  March 6, 2025

• Tris to ask for approval of dual-acting pain drug

  March 6, 2025

• Biogen buys rights to Stoke’s rare epilepsy drug

  Feb. 18, 2025

• ‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

  Feb. 14, 2025

• A brain biotech launches with Roche’s spare parts

  Feb. 13, 2025

• Bristol Myers gives first peek at closely watched launch of schizophrenia drug

  Feb. 6, 2025

• Shares of psychedelics biotech nearly double on depression data

  Feb. 3, 2025

• A new, non-opioid pain drug is here. Getting it to patients could be agony.

  Jan. 31, 2025

• Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

  Jan. 30, 2025

• Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world

  Jan. 16, 2025

• At JPM, Biogen CEO tries to take down the deal temperature

  Jan. 15, 2025

• Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street

  Jan. 13, 2025

• J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

  Jan. 13, 2025

• ALS drugs from Denali, Calico come up short, marking setback for Healey trial

  Jan. 7, 2025

• Neumora plummets on depression drug data

  Jan. 2, 2025

• Roche sticks with Parkinson’s drug despite second study failure

  Dec. 19, 2024

• Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint

  Dec. 19, 2024

• A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs

  Dec. 18, 2024

• CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug

  Dec. 13, 2024

• UniQure shares soar on chance of speedy approval for Huntington’s therapy

  Dec. 10, 2024

• GSK taps a startup for shot at Alzheimer’s drug

  Dec. 5, 2024

• Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M

  Dec. 4, 2024

• Novartis wagers billions of dollars on PTC Huntington’s drug

  Dec. 2, 2024

• How Intra-Cellular surprised Wall Street by breaking character

  Nov. 27, 2024

• Roche to buy cell therapy developer Poseida for $1B

  Nov. 26, 2024

• Alector turns to layoffs as Alzheimer’s drug fails

  Nov. 26, 2024

• Novartis wagers more than $1B on gene therapies for the nervous system

  Nov. 21, 2024

• Sage’s string of research failures continues

  Nov. 20, 2024

• How a Biogen drug set the stage for a new biotech targeting ALS

  Nov. 15, 2024

• Eisai wins over European regulators on Alzheimer’s drug Leqembi

  Nov. 14, 2024

• Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS

  Nov. 12, 2024

• On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned

  Nov. 11, 2024

• AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies

  Nov. 11, 2024

• Athira exploring strategic alternatives after Alzheimer’s failure

  Nov. 8, 2024

• Investors put $115M into Axonis amid revived interest in brain drugs

  Oct. 30, 2024

• Biogen optimistic as new products gain traction

  Oct. 30, 2024

• AbbVie to acquire a J&J-backed brain drugmaker for $1.4B

  Oct. 28, 2024

• Alto hits new low as depression drug flunks key test

  Oct. 23, 2024

• PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.

  Oct. 21, 2024

• Brain drug developer Seaport raises another $225M

  Oct. 21, 2024

• After rejections, AbbVie secures approval for Parkinson’s drug

  Oct. 17, 2024

• Lundbeck to buy brain drug developer Longboard for $2.6B

  Oct. 14, 2024

• Sanofi may have found a buyer for its consumer health business

  Oct. 11, 2024

• Sage continues downslide as Alzheimer’s study fails

  Oct. 8, 2024

• Sanofi’s rare disease drug finds yet another home

  Oct. 4, 2024

• Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug

  Sept. 26, 2024

• Struggling 2Seventy scraps a key cancer study

  Sept. 25, 2024

• Biogen, UCB get the lupus data they’ve waited two decades for

  Sept. 24, 2024

• After setback, Biohaven to seek approval of neurological disorder drug

  Sept. 23, 2024

• Investors are waking up to Centessa’s sleepiness drug

  Sept. 10, 2024

• Neurocrine’s mixed schizophrenia data disappoint Wall Street

  Aug. 28, 2024

• BioMarin taps Amgen, Roche vets in executive reshuffle

  Aug. 21, 2024

• Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy

  Aug. 15, 2024

• Incyte builds out its arsenal of post-transplant drugs

  Aug. 15, 2024

• Following FDA rejection, a journal retracts papers on MDMA-assisted therapy

  Aug. 12, 2024

• In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD

  Aug. 9, 2024

• Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

  Aug. 6, 2024

• As sales climb, Biogen ‘convinced’ the worst is over for Leqembi

  Aug. 1, 2024

• Leqembi voted down by European regulators

  July 26, 2024

• Sanofi’s immunology bet starts to pay off

  July 25, 2024

• Biogen, Sage tremor drug fails key trial

  July 24, 2024

• Ionis plots next steps for Angelman drug Biogen passed on

  July 22, 2024

• Asceneuron raises another $100M for Alzheimer’s drug development

  July 16, 2024

• Pfizer thinks it found its obesity pill

  July 11, 2024

• Amylyx, with GLP-1 buy, doubles down on blood sugar drugs

  July 10, 2024

• UniQure stock surges on data for Huntington’s gene therapy

  July 9, 2024

• Lilly to buy Morphic in $3B bet on inflammation drug

  July 8, 2024

• CureVac cuts jobs, licenses out vaccines to GSK

  July 3, 2024

• These microscopic tunnels are a goldmine for new medicines

  June 27, 2024

• Syncona melds two gene therapy biotechs for better shot at new nervous system treatments

  June 17, 2024

• Lilly Alzheimer’s drug gets unanimous backing of FDA panel

  June 10, 2024

• After ‘sobering’ FDA panel, psychedelics supporters wonder what’s next

  June 7, 2024

• FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns

  June 4, 2024

• FDA staff outline shortcomings of Lykos data for MDMA therapy

  May 31, 2024

• Orna, a circular RNA specialist, acquires a buzzy startup

  May 23, 2024

• Forbion-backed biotech Progentos debuts with $65M for MS drug

  May 20, 2024

• Biogen, Ionis shelve ALS drug following study failure

  May 16, 2024

• Eisai sets new revenue target for Alzheimer’s drug Leqembi

  May 15, 2024

• Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune

  May 13, 2024

• FDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug

  May 7, 2024

• Gossamer sells rights to drug it hopes can rival a new Merck therapy

  May 6, 2024

• Reunion raises over $100M to build a better psychedelic drug

  May 2, 2024

• Deciphera to sell for $2.4B, adding to upswing in biopharma M&A

  April 29, 2024

• Biogen: Don’t expect any big acquisitions this year

  April 24, 2024

• Biogen to invest more in launch of Alzheimer’s drug Leqembi

  April 24, 2024

• Neurocrine scores surprise win with depression drug

  April 23, 2024

• Sage’s cognition drug fails in Parkinson’s study

  April 17, 2024

• Intra-Cellular builds case for depression drug with late-stage trial win

  April 16, 2024

• Neumora’s schizophrenia drug hit with clinical hold

  April 15, 2024

• Roche, Adaptimmune part ways on cell therapy research

  April 12, 2024

• PureTech launches Seaport, hoping to create Karuna 2.0

  April 9, 2024

• Psychiatry drugs finally have pharma’s attention. Can they keep it?

  April 8, 2024

• Amylyx to pull ALS drug from market in rare move

  April 4, 2024

• Paragon’s hub-and-spoke biotech model yields another reverse merger

  April 3, 2024

• Acorda files for bankruptcy, reveals asset sale plan

  April 2, 2024

• European study finds popular ALS drug ineffective

  March 27, 2024

• Axsome drug succeeds in narcolepsy symptoms trial

  March 25, 2024

• Acelyrin eye drug heads to late-stage testing after trial win

  March 20, 2024

• Engrail’s precision psychiatry drugs get more buy in from venture investors

  March 19, 2024

• Bristol Myers cell therapy wins first-of-its-kind approval

  March 15, 2024

• After surprise trial failure, ALS doctors brace for one less treatment option

  March 12, 2024

• Amylyx CEOs look for a path forward following major setback

  March 11, 2024

• Amylyx ALS drug fails crucial study, putting company’s future in doubt

  March 8, 2024

• NodThera says inflammation drug has positive effect in Parkinson’s

  March 7, 2024

• Gilead bets on ‘trispecifics’ in latest cancer drug deal

  March 6, 2024

• Bayer isn’t splitting up, for now

  March 5, 2024

• Cure Ventures backs a cell therapy startup targeting Parkinson’s

  Feb. 29, 2024

• Incannex says psilocybin therapy lowered anxiety in small study

  Feb. 28, 2024

• NGM to go private through deal with investment firm

  Feb. 26, 2024

• AbbVie’s Cerevel deal hits an uncommon roadblock

  Feb. 20, 2024

• Intellia, ReCode partner on genetic medicines for cystic fibrosis

  Feb. 15, 2024

• Biogen has a fuzzy line of sight on prized Alzheimer’s drug

  Feb. 13, 2024

• Takeda speeds narcolepsy drug to late-stage testing

  Feb. 9, 2024

• Neurona raises another $120M for brain disease cell therapies

  Feb. 8, 2024

• Eisai falls behind on Leqembi patient goal

  Feb. 6, 2024

• J&J says top drug prospect works across autoimmune disorders

  Feb. 5, 2024

• Biogen quits Aduhelm, handing back rights to original developer

  Jan. 31, 2024

• Karuna, Cerevel might be just the start of psychiatry drug M&A

  Jan. 22, 2024

• Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi

  Jan. 8, 2024

• An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy

  Jan. 5, 2024

• 10 clinical trials to watch in the first half of 2024

  Jan. 2, 2024

• Clene says its ALS drug data is not yet enough for FDA

  Dec. 21, 2023

• As ALS research booms, one treatment center finds itself in the spotlight

  Dec. 20, 2023

• Investors still aren’t sold on UniQure’s gene therapy for Huntington’s

  Dec. 19, 2023

• Amgen finds a new top scientist in Novartis veteran Bradner

  Dec. 15, 2023

• AbbVie to buy Cerevel in $8.7B bet on brain drugs

  Dec. 6, 2023

• Pharvaris shares spike as drug appears to prevent symptoms of rare disorder

  Dec. 6, 2023

• European regulators want to know more about the risks of GLP-1 drugs

  Dec. 1, 2023

• Bristol Myers pours $100M into RNA drugs for cardiovascular diseases

  Nov. 28, 2023

• Xenon drug misses main goal of depression study

  Nov. 27, 2023

• AstraZeneca creates digital health unit, with big-name partnerships already in place

  Nov. 20, 2023

• Biogen says growth is coming, but won’t specify when

  Nov. 8, 2023

• A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s

  Oct. 30, 2023

• Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs

  Oct. 27, 2023

• Vertex gearing up for launch as sickle cell therapy review advances

  Oct. 26, 2023

• Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi

  Oct. 25, 2023

• BrainStorm, after setbacks, withdraws approval application for ALS drug

  Oct. 18, 2023

• Roche is stuck on molecular glue

  Oct. 17, 2023

• Amylyx’s ALS drug knocked back again in Europe

  Oct. 13, 2023

• After summer slump, biotech M&A has a good week

  Oct. 10, 2023

• NIH funds research for three experimental ALS drugs

  Oct. 6, 2023

• AbbVie acquires Parkinson’s drug in latest biotech buyout

  Oct. 5, 2023

• Regeneron, Intellia target neurological diseases in expanded gene editing deal

  Oct. 3, 2023

• Novartis’ closely watched rare disease drug scores in kidney disorder

  Oct. 2, 2023

• Seagen’s cancer drug succeeds in ‘must-win’ trial

  Sept. 22, 2023

• FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet

  Sept. 18, 2023

• New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs

  Sept. 12, 2023

• Alnylam says hypertension drug succeeded in mid-stage study

  Sept. 7, 2023

• Biogen, continuing executive revamp, finds a new research head

  Sept. 6, 2023

• FDA documents hint at ‘uphill battle’ for broad approval of Sage’s depression drug

  Sept. 1, 2023

• Sanofi appoints a venture investor to R&D head as executive team expands

  Aug. 31, 2023

• Bayer reports positive early data for Parkinson’s cell therapy

  Aug. 28, 2023

• FDA approves Novartis’ copycat of blockbuster Biogen drug

  Aug. 25, 2023

• J&J-backed startup raises another $150M for brain drug development

  Aug. 23, 2023

• FDA expands use of Neurocrine drug to Huntington’s patients

  Aug. 21, 2023

• Merck says drug acquired in $1B buyout scores in large kidney cancer study

  Aug. 18, 2023

• J&J grows cancer drug portfolio with newly approved bispecific

  Aug. 10, 2023

• Emergent to lay off around 400 in pivot away from contract manufacturing

  Aug. 8, 2023

• Sage considers cuts after FDA’s split decision on depression drug

  Aug. 7, 2023

• FDA approves Sage, Biogen drug for postpartum depression, but rejects wider use

  Aug. 4, 2023

• TG shares tumble following licensing deal for MS drug

  Aug. 1, 2023

• Idorsia warns of up to 500 layoffs as part of cost-cutting initiative

  July 21, 2023

• Sanofi, searching for new immune system drugs, partners with a young biotech

  July 20, 2023

• An Arch-backed biotech pushes its depression drug into late-stage testing

  July 18, 2023

• Lilly Alzheimer’s drug slowed disease by roughly half a year, new results show

  July 17, 2023

• Westlake raises $450M in latest biotech venture fund

  July 17, 2023

• Eisai’s Ivan Cheung, who oversaw Alzheimer’s drug success, to depart

  July 11, 2023

• FDA grants Eisai’s Leqembi full approval, opening door to wider use of Alzheimer’s drug

  July 6, 2023

• With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy

  June 30, 2023

• BioMarin finally secures FDA approval of hemophilia gene therapy

  June 29, 2023

• Lilly takes over partner working on cell therapies for diabetes

  June 29, 2023

• Sanofi chalks up another win for its immune system research

  June 27, 2023

• Biogen shareholders vote in favor of new board member

  June 26, 2023

• 5 FDA decisions to watch in the third quarter

  June 26, 2023

• Amylyx’s ALS drug gets pushback from European regulators

  June 23, 2023

• Roivant reports more positive data for inflammation drug

  June 22, 2023

• UniQure stock tumbles on ‘confusing’ results for Huntington’s gene therapy

  June 21, 2023

• Coherus doubles down on immuno-oncology with latest deal

  June 16, 2023

• Biogen’s latest board shake-up includes potentially controversial pick

  June 13, 2023

• Built from biotech parts, Beacon launches with $120M to develop eye gene therapies

  June 12, 2023

• FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug

  June 9, 2023

• Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi

  June 7, 2023

• FDA sets advisory meeting date for Brainstorm’s ALS cell therapy

  June 6, 2023

• Biogen scraps late-stage study for Parkinson’s drug

  June 5, 2023

• Wave shelves ALS drug following trial setback

  May 23, 2023

• Ironwood to buy rare disease drugmaker in billion-dollar deal

  May 22, 2023

• Moderna reports ‘encouraging’ early data for one of its rare disease medicines

  May 19, 2023

• Mustang pares research, sells manufacturing plant to save money

  May 18, 2023

• PTC’s drug for PKU succeeds in late-stage clinical trial

  May 17, 2023

• A struggling biotech wraps its main assets into a new drug company

  May 12, 2023

• Amylyx’s ALS drug again surpasses Wall Street expectations

  May 11, 2023

• Alzheimer’s doctors see promise, limits in Lilly’s latest drug data

  May 10, 2023

• Lilly’s new Alzheimer’s data may both help and hinder rival Biogen

  May 3, 2023

• FDA approves new ALS medicine in precedent-setting decision

  April 25, 2023

• Biogen’s new strategy brings more pipeline cuts, but leaves deal options open

  April 25, 2023

• Apellis’ immune system drug hits a setback in ALS

  April 21, 2023

• Merck’s latest deal turns up the spotlight on immune system drugmakers

  April 17, 2023

• A biotech startup with big-name backers aims to create new cancer medicines

  April 14, 2023

• Biogen, aiming for a better Alzheimer’s therapy, licenses a Denali program

  April 13, 2023

• Novo’s latest deal targets cell therapy for diabetes, obesity

  April 12, 2023

• A new biotech wants to ease a bottleneck in cell and gene therapy production

  April 11, 2023

• Ginkgo grows its gene therapy offerings with StrideBio deal

  April 5, 2023

• Biogen taps a deals expert in latest C-suite appointment

  April 4, 2023

• 5 FDA decisions to watch in the second quarter

  April 3, 2023

• Cytokinetics to end late-stage study of ALS drug

  March 31, 2023

• A brain drug developer joins a growing list of biotech layoffs

  March 30, 2023

• Intra-Cellular shares rise on depression study’s success

  March 28, 2023

• ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein

  March 27, 2023

• FDA advisers support conditional clearance of Biogen’s ALS drug

  March 22, 2023

• FDA staff signal support for Biogen ALS drug, but highlight data hurdles

  March 20, 2023

• Karuna’s schizophrenia drug succeeds in a second late-stage trial

  March 20, 2023

• Amylyx’s ALS drug sales impress Wall Street

  March 13, 2023

• J&J-backed startup launches with $100M to build better brain drugs

  March 7, 2023

• Despite study setback, a biotech plans to push tremor drug into late-stage testing

  March 3, 2023

• Novo Nordisk to create Boston R&D hub

  March 2, 2023

• Following another trial failure, a brain biotech considers ‘strategic alternatives’

  Feb. 28, 2023

• Seagen reportedly in sales talks again, this time with Pfizer

  Feb. 27, 2023

• Novartis backs away from NASH, furthering its research revamp

  Feb. 24, 2023

• FDA approves Sanofi’s long-lasting hemophilia drug

  Feb. 23, 2023

• Moderna inks another gene editing deal

  Feb. 22, 2023

• With sales falling, Biogen’s new CEO says transformation is needed

  Feb. 15, 2023

• Sanofi R&D head John Reed leaves to take similar role at J&J

  Feb. 13, 2023

• Cigna restricts coverage of new ALS drug, deepening fears about access

  Feb. 7, 2023

• Eisai gives first glimpse into Alzheimer’s drug launch

  Feb. 6, 2023

• Karuna, hoping to find new brain drugs, buys up a shuttering biotech’s pipeline

  Feb. 2, 2023

• Novartis confirms it has stopped development of experimental Huntington’s drug

  Feb. 1, 2023

• UniQure nabs another gene therapy for ALS

  Jan. 31, 2023

• J&J, Legend’s cancer cell therapy has early success in key clinical trial

  Jan. 27, 2023

• Sales of J&J, Legend cell therapy plateau amid production challenges

  Jan. 25, 2023

• FDA to seek outside advice on Biogen’s ALS drug

  Jan. 24, 2023

• Why Wall Street shrugged at Lilly’s Alzheimer’s setback

  Jan. 20, 2023

• 3 biotech executives on the year ahead: deals, drug pricing and the down market

  Jan. 19, 2023

• JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

  Jan. 11, 2023

• JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

  Jan. 10, 2023

• JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

  Jan. 10, 2023

• FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

  Jan. 6, 2023

• Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus

  Jan. 4, 2023

• Gilead buys Tmunity, cozying up to a CAR-T pioneer

  Dec. 20, 2022

• Madrigal shares triple on positive NASH study results

  Dec. 19, 2022

• European regulators back hemophilia gene therapy

  Dec. 16, 2022

• For ALS patients, doctors, a new medicine reignites concerns about healthcare access

  Dec. 15, 2022

• Clovis files for bankruptcy

  Dec. 12, 2022

• Gilead buys into multiple myeloma cell therapy with Arcellx deal

  Dec. 9, 2022

• Vertex invests in a rare disease drug and its developer

  Dec. 8, 2022

• Prometheus shares soar on new data for inflammation drug

  Dec. 7, 2022

• Pfizer, Roivant set up new company around inflammation drug

  Dec. 1, 2022

• What to make of Eisai and Biogen’s Alzheimer’s drug results

  Nov. 29, 2022

• Axsome says drug eased Alzheimer’s symptom in positive study

  Nov. 28, 2022

• Narcan developer to be acquired by Indivior

  Nov. 14, 2022

• FDA declines to review Brainstorm’s ALS therapy

  Nov. 11, 2022

• Centerview grows role as go-to adviser for biopharma dealmaking

  Nov. 8, 2022

• Galapagos to cut 200 jobs amid research revamp

  Nov. 4, 2022

• Abeona to submit cell therapy for approval after positive results for skin disorder treatment

  Nov. 3, 2022

• String of gene therapy deals spurs cautious optimism on Wall Street

  Nov. 1, 2022

• Gilead, fueled by latest approval, sees CAR-T sales take off

  Oct. 28, 2022

• BioMarin to face FDA advisers before approval decision on hemophilia gene therapy

  Oct. 27, 2022

• For Biogen investors, company’s outlook rests on next Alzheimer’s drug

  Oct. 25, 2022

• Myovant agrees to sell after buyer ups price

  Oct. 24, 2022

• Lilly bets more than $600M on a gene therapy developer targeting hearing loss

  Oct. 18, 2022

• Biogen expects longer wait on ALS drug decision from FDA

  Oct. 17, 2022

• 5 questions facing drugmakers as third quarter earnings begin

  Oct. 17, 2022

• Enliven to enter public markets through reverse merger with Imara

  Oct. 14, 2022

• BioMarin to lay off about 120 employees as part of restructuring plan

  Oct. 7, 2022

• A Versant-backed biotech emerges to take on ‘overlooked’ cancer targets

  Oct. 6, 2022

• Biogen, Denali begin late-stage testing of Parkinson’s drug

  Oct. 3, 2022

• 5 FDA decisions to watch in the fourth quarter

  Oct. 3, 2022

• Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost

  Sept. 30, 2022

• ALS drug approved by FDA in closely watched decision, marking win for patients, developer

  Sept. 29, 2022

• With little data to go on, experts question how useful Eisai, Biogen’s new Alzheimer’s drug will be

  Sept. 29, 2022

• Vertex given green light to seek US approval of CRISPR-based therapy

  Sept. 27, 2022

• Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

  Sept. 26, 2022

• FDA advisers back Amylyx ALS drug, reversing earlier position

  Sept. 7, 2022

• Neurocrine, with latest deal, gets a foothold in Europe

  Aug. 30, 2022

• Incyte secures second approval for targeted cancer drug

  Aug. 29, 2022

• With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy

  Aug. 25, 2022

• Backed by $40M, a biotech startup targets cancer with help from the immune system

  Aug. 25, 2022

• Next-generation RNA technologies: making longer-lasting drugs with a broader reach

  Aug. 23, 2022

• Gilead, with new results, doubles down on breast cancer drug

  Aug. 16, 2022

• Despite failed trial, Brainstorm asks FDA to approve ALS drug

  Aug. 15, 2022

• Karuna shares soar on schizophrenia drug results

  Aug. 8, 2022

• Amgen bets almost $4B on a biotech and its inflammation drugs

  Aug. 4, 2022

• Gilead, following cell therapy approval, impresses Wall Street with fast sales

  Aug. 3, 2022

• AbbVie, targeting a well-known protein family, expands a partnership into neuroscience

  Aug. 2, 2022

• Nuvation to cut workforce by 35% as it scraps lead drug program

  Aug. 1, 2022

• Novartis-linked startup launches with technology designed to remove ‘destroy’ tags on helpful proteins

  July 28, 2022

• FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug

  July 26, 2022

• With Aduhelm sidelined, Wall Street turns to Biogen's next Alzheimer's drug

  July 20, 2022

• FDA approves new vitiligo treatment, bolstering Incyte's dermatology business

  July 19, 2022

• Ultragenyx sells rare disease drug royalties to Canadian pension fund

  July 15, 2022

• Agios CEO to step down, handing role to veteran in rare disease drug sales

  July 12, 2022

• Vertex acquires another maker of potentially curative diabetes treatments

  July 11, 2022

• After a lengthy drought, could biotech M&A be on the upswing?

  July 8, 2022

• New analysis encourages Intercept to refile NASH drug for approval

  July 7, 2022

• In 'unusual' move, FDA to reconvene advisers for ALS drug review

  July 5, 2022

• 10 clinical trials to watch in the second half of 2022

  July 5, 2022

• Blueprint secures access to more than $1B in funding through two new deals

  June 30, 2022

• 5 FDA decisions to watch in the third quarter

  June 29, 2022

• Arch brings in another $3B for biotech startup investing

  June 29, 2022

• Jazz drug fails in late-stage study for multiple sclerosis

  June 28, 2022

• BioMarin's hemophilia gene therapy recommended for approval in Europe

  June 24, 2022

• Biogen, citing insurance challenges, shutters one of its Aduhelm studies

  June 22, 2022

• Galapagos, with latest deals, charts an unexpected journey to cell therapy

  June 22, 2022

• Roche Alzheimer's study fails in another setback to a long-tested hypothesis

  June 16, 2022

• With biotech in retreat, Third Rock raises $1B for life sciences investing

  June 15, 2022

• Amylyx's ALS drug gets approved in Canada

  June 13, 2022

• Vertex, CRISPR strengthen case for pioneering gene-editing treatment

  June 11, 2022

• Astellas, despite recent setbacks, opens $100M gene therapy plant

  June 8, 2022

• Amarin turns to job cuts as generics challenge its heart pill

  June 6, 2022

• Yumanity's days as an independent biotech come to a close

  June 6, 2022

• Detailed study data show modest benefit to Gilead breast cancer drug

  June 4, 2022

• Biohaven hits setback as it moves beyond migraine

  May 23, 2022

• AbbVie asks FDA to approve Parkinson’s treatment

  May 20, 2022

• Gilead, having resolved manufacturing issues, forges ahead with HIV drug

  May 17, 2022

• Agios to cut jobs as it moves away from exploratory research

  May 16, 2022

• FDA approves oral version of Mitsubishi's ALS drug

  May 13, 2022

• Moderna's finance head is out as former employer conducts investigation

  May 11, 2022

• Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs

  May 10, 2022

• Against a historic market downturn, Moma Therapeutics raises $150M for precision cancer research

  May 10, 2022

• Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

  May 4, 2022

• Biogen CEO to step down as company pulls back from Alzheimer’s drug

  May 3, 2022

• A cancer biotech attracts another deep-pocketed partner in Gilead

  May 2, 2022

• AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis

  April 29, 2022

• After setbacks, a gene therapy company mulls a sale

  April 28, 2022

• Undeterred by gene therapy's struggles, a startup launches into a downturn

  April 26, 2022

• Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug

  April 22, 2022

• Seagen to expand, add jobs with new cancer drug factory

  April 21, 2022

• A promising cancer drug leads Regeneron to reconsider its aversion to M&A

  April 19, 2022

• Troubling data leads a biotech to pull its prized drug from market and FDA review

  April 18, 2022

• Editas CEO to step down in latest executive change-up

  April 14, 2022

• Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B

  April 13, 2022

• Regeneron, in search of an eye gene therapy, turns to a young biotech

  April 6, 2022

• FDA clears second Novartis plant for gene therapy manufacturing

  April 5, 2022

• Alnylam to wait longer for FDA verdict on latest RNA drug

  April 4, 2022

• Yet another gene therapy developer turns to layoffs

  April 1, 2022

• 5 FDA decisions to watch in the second quarter

  March 31, 2022

• FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances

  March 30, 2022

• How a long shot ALS drug came before the FDA

  March 28, 2022

• Al Sandrock takes on CEO role at gene therapy developer

  March 22, 2022

• FDA approves new epilepsy drug, handing Marinus a long-awaited victory

  March 21, 2022

• Biogen and its partner rework terms of Aduhelm deal amid slow sales

  March 15, 2022

• AbbVie keeps up dealmaking pace in neuroscience

  March 11, 2022

• After slower-than-expected review, Pfizer and Arena close buyout deal

  March 10, 2022

• Sanofi, with positive data in hand, to ask for approval of longer-lasting hemophilia therapy

  March 9, 2022

• Novartis turns to Voyager for nervous system gene therapies

  March 8, 2022

• Gilead says breast cancer drug succeeded in key study, but offers few details

  March 7, 2022

• Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money

  March 3, 2022

• FDA rejects Gilead's closely watched HIV drug

  March 1, 2022

• Viatris sells off biosimilars business in $3.3B deal

  Feb. 28, 2022

• Biohaven stocks up on experimental drugs with new acquisition, licensing deal

  Feb. 25, 2022

• Lilly puts $700M into genetic medicine institute

  Feb. 22, 2022

• With drug approval, Agios hits first key milestone after major shakeup

  Feb. 18, 2022

• Yumanity cutting 60% of employees as it mulls possible sale

  Feb. 17, 2022

• Star Therapeutics emerges with plans to treat rare diseases through a solar system of drug companies

  Feb. 16, 2022

• Seagen shares sink as sales outlook of cancer drug disappoints

  Feb. 10, 2022

• Editas' executive shake-up continues

  Feb. 8, 2022

• More federal regulators investigating Biogen Alzheimer's drug

  Feb. 4, 2022

• Biogen's Alzheimer's drug sales remain slow as company warns of further cost cuts

  Feb. 3, 2022

• Pressure rises as Gilead awaits important study results for top cancer drug

  Feb. 2, 2022

• Madrigal adds to safety data for NASH drug

  Jan. 31, 2022

• Biogen, facing pressure on all sides, sells stake in biosimilars business

  Jan. 28, 2022

• Touting a new way to drug an all-important family of proteins, a startup launches with $100M

  Jan. 27, 2022

• Sierra Oncology records success in late-stage study of bone cancer drug

  Jan. 25, 2022

• Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.

  Jan. 21, 2022

• FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

  Jan. 18, 2022

• Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug

  Jan. 14, 2022

• 5 questions facing biotech M&A in 2022

  Jan. 12, 2022

• Medicare proposes to limit coverage of Biogen Alzheimer's drug

  Jan. 11, 2022

• JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies

  Jan. 10, 2022

• Lilly pours more money into genetic treatments for neurological diseases

  Jan. 6, 2022

• 5 FDA approval decisions to watch in the first quarter

  Jan. 5, 2022

• Biogen brings in a successor to Spinraza

  Jan. 4, 2022

• Gilead, following Merck, hits its own safety setback in HIV

  Dec. 22, 2021

• GSK's long-acting HIV shot approved for preventive use

  Dec. 21, 2021

• After intense pushback, Biogen to cut price of Alzheimer's drug

  Dec. 20, 2021

• European regulators say no to Aduhelm, but Biogen is pushing back

  Dec. 17, 2021

• Biogen reserves four years for trial meant to confirm its Alzheimer's drug works

  Dec. 16, 2021

• Lilly ups revenue forecast amid windfall from COVID-19 drugs

  Dec. 15, 2021

• On the hunt for new ALS drugs, researchers see progress, and a long road ahead

  Dec. 13, 2021

• Fresh data show UniQure's hemophilia gene therapy appears to hold up

  Dec. 9, 2021

• A high-profile gene therapy biotech takes aim at Huntington's

  Dec. 8, 2021

• AbbVie's blockbuster weighed down by safety concerns for a similar Pfizer drug

  Dec. 6, 2021

• Sobi buyout breaks down

  Dec. 3, 2021

• GSK sets sights on brain diseases through Oxford partnership

  Dec. 2, 2021

• With safety a concern, Merck, Gilead pause study of HIV drugs

  Nov. 24, 2021

• GSK dives into NASH, RNA interference with Arrowhead deal

  Nov. 23, 2021

• Neurocrine stocks up on a biotech's psychiatric drugs

  Nov. 22, 2021

• A worrisome safety signal slows Merck's HIV ambitions

  Nov. 19, 2021

• Al Sandrock, Biogen's top scientist and Aduhelm defender, to retire in surprise exit

  Nov. 16, 2021

• Moderna founder unveils new drug company focused on a different kind of RNA

  Nov. 9, 2021

• Novartis to sell long-held stake in Roche for nearly $21B

  Nov. 4, 2021

• Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments

  Nov. 3, 2021

• Amylyx asks FDA to approve ALS drug, while also preparing late-stage study

  Nov. 2, 2021

• Despite strong quarter, some wonder how long Gilead can rely on coronavirus drug

  Oct. 29, 2021

• With approval plans underway, Lilly's next move is to test its Alzheimer's drug against Biogen's

  Oct. 26, 2021

• With Merck blocking its path, a small biotech reroutes, to the dismay of investors

  Oct. 22, 2021

• Biogen's Alzheimer's drug is struggling, and a turnaround might not be coming soon

  Oct. 20, 2021

• Sage, Biogen detail plans to get their newer depression drug approved

  Oct. 19, 2021

• Biogen's closely watched ALS drug comes up short in late-stage study

  Oct. 18, 2021

• Intellia looks to eye diseases in latest deal

  Oct. 13, 2021

• Takeda takes aim at a biotech's gene therapy work

  Oct. 12, 2021

• Armed with half a billion dollars, a startup aims to change how brain drugs are made

  Oct. 7, 2021

• 5 FDA approval decisions to watch in the fourth quarter

  Oct. 1, 2021

• Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck

  Sept. 30, 2021

• Bluebird officially asks FDA to approve gene therapy for rare blood disorder

  Sept. 22, 2021

• Theravance to lay off 75% of employees alongside larger restructuring

  Sept. 15, 2021

• After talks with FDA, a biotech prepares to submit its closely watched ALS drug

  Sept. 15, 2021

• Biotech funder Lightstone raises another $375M for life sciences investing

  Sept. 14, 2021

• AbbVie bets big on a gene therapy for eye diseases

  Sept. 13, 2021

• Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.

  Sept. 9, 2021

• Venture capital pours more money into RNA medicines with the launch of Replicate

  Sept. 8, 2021

• With safety worries mounting, FDA limits who can take certain immune-regulating drugs

  Sept. 1, 2021

• Astellas again hits pause on gene therapy trial

  Sept. 1, 2021

• Galapagos CEO to retire, though successor yet to be announced

  Aug. 31, 2021

• Moderna founder's next big play in RNA raises $440M

  Aug. 30, 2021

• Lilly puts more money into protein degradation

  Aug. 25, 2021

• Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

  Aug. 24, 2021

• J&J chief Alex Gorsky to step down early next year

  Aug. 20, 2021

• Private equity dives deeper into biotech with nearly $2B Bain fundraise

  Aug. 17, 2021

• Lilly's new eczema drug scores in late-stage studies

  Aug. 16, 2021

• Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

  Aug. 10, 2021

• Bluebird to wind down business in Europe amid gene therapy struggles

  Aug. 9, 2021

• HHS watchdog to review FDA accelerated approval process after Aduhelm controversy

  Aug. 4, 2021

• After controversial approval, doctors are still debating how to use Biogen's Alzheimer's drug

  Aug. 3, 2021

• FDA rejects a biotech's kidney drug, but some analysts still see a 'sliver of hope'

  July 30, 2021

• Biogen, Ionis tout data from early study of RNA-based Alzheimer's drug

  July 27, 2021

• Denali drug for rare brain disease disappoints investors

  July 26, 2021

• Major health centers, insurers push back against Aduhelm

  July 15, 2021

• Biohaven CEO on migraine drug's fast launch, TikTok ads and battling big pharma

  July 14, 2021

• Bluebird resumes marketing gene therapy in Europe

  July 9, 2021

• Gene therapy for sickle cell disease: progress and competition

  July 8, 2021

• FDA knocks back diabetes prevention drug, crushing its maker's shares

  July 6, 2021

• GSK returns to brain drugs with major biotech deal

  July 2, 2021

• Pfizer's neuroscience spinout scores in schizophrenia

  June 29, 2021

• European regulators push 8 drugs toward approval, including controversial anemia pill

  June 25, 2021

• With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt

  June 24, 2021

• FDA documents show how controversial Alzheimer's drug decision was reached

  June 22, 2021

• A year after getting UniQure's gene therapy, hemophilia patients are still doing better

  June 22, 2021

• Public Citizen calls for top FDA officials to resign following Alzheimer's drug approval

  June 16, 2021

• Biogen gene therapy deal has yet to bear fruit

  June 15, 2021

• Moderna founder raises another $2B to fuel new startups

  June 14, 2021

• Vertex stops work on second rare disease drug after study results disappoint

  June 10, 2021

• A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it

  June 8, 2021

• In historic move, FDA approves a closely watched and controversial Alzheimer's drug

  June 7, 2021

• Biotech venture capital still booming as venBio raises another $550M

  June 3, 2021

• Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug

  June 1, 2021

• A biotech backs off NASH after trial failure

  May 24, 2021

• Bluebird's next gene therapy gets backing from European regulator

  May 21, 2021

• In the midst of a 'strategic shift,' Voyager loses CEO and R&D head

  May 20, 2021

• FDA approval sets stage for a showdown between Alexion and Apellis

  May 17, 2021

• Third Rock launches biotech targeting 'notoriously difficult' DNA regulators

  May 13, 2021

• Biogen looks to build better gene therapies through latest deal

  May 11, 2021

• Moderna founder launches new biotech, looking to cure diseases through 'endless RNA'

  May 10, 2021

• Sage braces for make-or-break depression data

  May 4, 2021

• Wall Street fears Amgen's tough first quarter is just the start

  April 28, 2021

• Under pressure, Biogen will allow some patients early access to experimental ALS drug

  April 27, 2021

• Vertex moves pain drug into mid-stage testing

  April 26, 2021

• As review of its Alzheimer's drug wraps up, Biogen prepares for an uncertain launch

  April 22, 2021

• With money pouring into biotech, Versant raises another $950M

  April 21, 2021

• The next 2 months in biotech and pharma will be busy. Here's what to watch.

  April 20, 2021

• Vertex bets another $900M on CRISPR treatment for blood diseases

  April 20, 2021

• FDA faces backlash after seeking more data on an experimental ALS therapy

  April 14, 2021

• Gilead stops Veklury study, citing enrollment challenges, changing treatment

  April 13, 2021

• Provention Bio latest drugmaker flagged for 'deficiencies' in FDA approval application

  April 9, 2021

• Biogen adds a late-stage prospect to its growing biosimilar business

  April 8, 2021

• New data push a biotech's muscle disease drug closer to a key test

  April 6, 2021

• Acadia, with drug application rejected, calls out FDA for backtracking

  April 5, 2021

• FDA advisers reassert case against approval of Biogen's Alzheimer's drug

  March 31, 2021

• A biotech shelves its Huntington's drugs after trial failures

  March 30, 2021

• 5 FDA approval decisions to watch in the second quarter

  March 29, 2021

• Pfizer and Lilly's pain drug hits setback in negative committee vote

  March 26, 2021

• Drugmakers flock to Vineti's fix for a cell, gene therapy problem

  March 24, 2021

• José Baselga, prominent cancer researcher, dies at 61

  March 22, 2021

• AbbVie's approval delay raises further concerns about JAK drugs

  March 18, 2021

• Global Blood takes on more sickle cell drugs through Sanofi deal

  March 16, 2021

• Gilead, Merck combine forces in HIV

  March 15, 2021

• Vertex begins human testing for diabetes cell therapy

  March 10, 2021

• Acadia shares plunge after unexpected FDA feedback

  March 9, 2021

• Merck gives an early peek at COVID-19 drug results

  March 8, 2021

• Galapagos reports long-awaited safety data for inflammation drug

  March 4, 2021

• Takeda takes full control of drug for rare epilepsies

  March 3, 2021

• A closely watched schizophrenia drug fails key test

  March 2, 2021

• Sarepta wins FDA approval of another drug for rare muscular dystrophy

  Feb. 25, 2021

• Merck to buy autoimmune drugmaker for $2B

  Feb. 25, 2021

• After FDA feedback, a biotech's ALS therapy faces murky path forward

  Feb. 22, 2021

• Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems

  Feb. 18, 2021

• Gates Foundation backs Novartis' search for a sickle cell cure

  Feb. 17, 2021

• AbbVie exploring how CRISPR gene editing can improve cell therapies

  Feb. 10, 2021

• Lilly CFO steps down after investigation found 'inappropriate' behavior

  Feb. 9, 2021

• Biogen laser-focused on Alzheimer's drug as rest of business falters

  Feb. 3, 2021

• Vertex comes to a crossroads

  Feb. 2, 2021

• Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca

  Feb. 1, 2021

• FDA delays verdict for Biogen's closely watched Alzheimer's drug, raising investor optimism

  Jan. 29, 2021

• Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others

  Jan. 27, 2021

• FDA approves first-of-its-kind lupus drug

  Jan. 25, 2021

• Long-acting HIV drug secures FDA approval, giving GSK a competitive boost

  Jan. 22, 2021

• Biohaven adds to a long list of Alzheimer's drug failures

  Jan. 19, 2021

• Dana-Farber launches venture fund targeting incurable cancers

  Jan. 15, 2021

• 5 trends in biotech dealmaking to watch in 2021

  Jan. 13, 2021

• Lilly rockets up on mixed Alzheimer's results

  Jan. 11, 2021

• Alnylam, with positive data in hand, prepares to submit 4th drug for approval

  Jan. 7, 2021

• Dewpoint forges another big pharma partnership — and a potential rivalry

  Jan. 6, 2021

• A new, well-connected biotech aims to fight cancer with viruses

  Jan. 5, 2021

• Amgen's asthma drug takes a hit, making for stiffer competition with Regeneron

  Dec. 22, 2020

• Cancer case puts UniQure's hemophilia gene therapy on hold, raising alarms

  Dec. 21, 2020

• Novartis acquires a small biotech and its trio of brain drugs

  Dec. 17, 2020

• Gilead hands back some rights to key drug from Galapagos deal

  Dec. 16, 2020

• Pharmacquired: What a surprise deal does for AstraZeneca and Alexion

  Dec. 16, 2020

• AstraZeneca to buy Alexion for $39B

  Dec. 12, 2020

• Lilly's coronavirus drug partner nails down one of biotech's largest IPOs

  Dec. 11, 2020

• Gilead inks a billion-dollar deal for a hepatitis drug

  Dec. 10, 2020

• Armed with big pharma cash, another startup takes aim at mysterious clusters of molecules

  Dec. 9, 2020

• UniQure offers a closer look at the leading hemophilia B gene therapy

  Dec. 8, 2020

• Lilly, UnitedHealth explore how to best use a COVID-19 antibody drug

  Dec. 4, 2020

• 4 storylines to track at the year's biggest meeting on blood diseases

  Dec. 3, 2020

• J&J pushes further into eye gene therapy

  Dec. 2, 2020

• Biogen stocks up on Sage's brain drugs in $3B deal

  Nov. 27, 2020

• How Gilead finally spent its money

  Nov. 24, 2020

• Lilly dives into gene editing

  Nov. 20, 2020

• Stem cell therapy for ALS fails a large clinical trial

  Nov. 17, 2020

• Japanese drugmaker takes full control of a Roivant biotech

  Nov. 13, 2020

• Amgen's asthma drug delivers a needed win

  Nov. 10, 2020

• 5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug

  Nov. 9, 2020

• FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt

  Nov. 6, 2020

• Biogen surges as FDA reviewers appear supportive of Alzheimer's drug approval

  Nov. 4, 2020

• The meeting that could change Alzheimer's treatment

  Nov. 3, 2020

• Regeneron pauses study of rare disease drug following patient deaths

  Nov. 2, 2020

• Novartis eyes its next move in gene therapy

  Oct. 29, 2020

• Bristol Myers taps machine-learning biotech for help finding ALS drugs

  Oct. 28, 2020

• Sarepta, continuing its gene therapy push, helps launch a startup

  Oct. 22, 2020

• Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales

  Oct. 21, 2020

• Biogen is running out of safety nets

  Oct. 21, 2020

• Early signs of survival benefit raise optimism around a small biotech's ALS drug

  Oct. 16, 2020

• Vertex faces first notable setback as it pushes beyond cystic fibrosis

  Oct. 14, 2020

• Gossamer plummets as its lead drug fails 2 studies

  Oct. 13, 2020

• Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire

  Oct. 8, 2020

• With a sweetened offer, BridgeBio plans to reel in a subsidiary

  Oct. 5, 2020

• Pfizer pushes deeper into China with stake in cancer biotech

  Sept. 30, 2020

• Biogen's all-important Alzheimer's drug enters the review gauntlet

  Sept. 29, 2020

• After setback in the US, Galapagos' main drug finds success elsewhere

  Sept. 28, 2020

• GSK inhaler locks down a coveted approval in asthma

  Sept. 10, 2020

• Sanofi's hemophilia drug comes into focus as delays hit a key competitor

  Sept. 10, 2020

• Intra-Cellular roars back on success in bipolar depression

  Sept. 9, 2020

• Cancer drug approval puts Blueprint up against Lilly

  Sept. 8, 2020

• AbbVie wagers up to $2B on a Chinese biotech's cancer drug

  Sept. 4, 2020

• FDA scolds Mylan for 'repeated' manufacturing problems

  Sept. 3, 2020

• After a rare win, a biotech details long-awaited results for its ALS drug

  Sept. 2, 2020

• Gilead deal reignites optimism in a cancer biotech

  Sept. 1, 2020

• Ionis, changing its strategy, reels its spinoff back in

  Aug. 31, 2020

• With latest data, a gene therapy for a deadly brain disease inches closer to market

  Aug. 29, 2020

• BioMarin's hemophilia gene therapy could have warranted a record price tag, ICER finds

  Aug. 28, 2020

• New data lead Ovid, Takeda to push seizure drug into final testing

  Aug. 25, 2020

• Proteostasis bows out of cystic fibrosis drugmaking through Yumanity merger

  Aug. 24, 2020

• BioMarin's gene therapy rejection didn't shock everyone

  Aug. 20, 2020

• In major surprise, FDA rejects high-profile therapies from BioMarin, Gilead

  Aug. 19, 2020

• A cure for hemophilia seemed closer than ever. For many patients, it’s now further out of reach

  Aug. 18, 2020

• Bayer, contrasting pharma peers, builds up women's health business with $425M deal

  Aug. 11, 2020

• Seres finds the microbiome data it's been waiting for

  Aug. 10, 2020

• FDA agrees to review Biogen's Alzheimer's drug

  Aug. 7, 2020

• Biogen makes a billion-dollar bet on Parkinson's drugs

  Aug. 6, 2020

• FDA rejects a peanut allergy treatment, sinking a small biotech's shares

  Aug. 4, 2020

• Big pharma alliance recruits first patients for unusual COVID-19 study

  Aug. 3, 2020

• Vaccine sales driven down by pandemic's effects on doctor visits

  July 31, 2020

• Can Sanofi's top drug carry it through a pandemic?

  July 29, 2020

• Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing

  July 27, 2020

• Gilead's second act in cell therapy gets its first approval

  July 24, 2020

• UK to spend almost $130M more on coronavirus vaccine manufacturing

  July 23, 2020

• Biogen points to COVID-19 for disappointing drug launch

  July 22, 2020

• At a pivotal moment, Biogen loses another top executive

  July 22, 2020

• Gilead adds to string of cancer drug deals with Tizona stake

  July 21, 2020

• GSK invests in mRNA vaccines through deal with CureVac

  July 20, 2020

• Sanofi, on the lookout for acquisitions, may have spotted a target

  July 17, 2020

• Blackstone caps off private equity's largest-ever life sciences fund

  July 10, 2020

• Big pharma, battling COVID-19, looks to 'buy time' on another health crisis: superbugs

  July 9, 2020

• In the hunt for ALS treatments, researchers find promise in silencing genes

  July 8, 2020

• Biogen submitted its Alzheimer's drug for approval. Now what?

  July 8, 2020

• Bellus shares plummet as cough drug fails Phase 2 test

  July 6, 2020

• Amgen prevails in high-stakes drug case against Novartis

  July 1, 2020

• Gilead pricing suggests it will make a business out of COVID-19 drug

  June 30, 2020

• Intercept's NASH drug faces its biggest delay yet

  June 29, 2020

• FDA rejects AbbVie's eye drug, citing safety concerns

  June 26, 2020

• Sanofi's fight for a better research reputation

  June 23, 2020

• Sarepta tries to fine-tune its gene therapy approach

  June 22, 2020

• In big year for microbiome drugs, a small biotech sets the bar

  June 19, 2020

• Sanofi's latest investment signals long-term focus on vaccines

  June 16, 2020

• Neurocrine bets $2B on Takeda's psychiatry drugs

  June 16, 2020

• Magenta's technology attracts another gene therapy developer

  June 15, 2020

• Agios, seeking a new strategy, touts positive data and marketing deal

  June 12, 2020

• Lundbeck to cut more than 100 jobs as it remodels R&D

  June 9, 2020

• Amid a pandemic, Atlas becomes latest venture firm to raise cash for drug startups

  June 5, 2020

• Pfizer business head details new $500M project for investing in public biotechs

  June 3, 2020

• Details lacking, but new remdesivir data point to a benefit for 'moderate' COVID-19 patients

  June 1, 2020

• Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'

  May 29, 2020

• Contaminated diabetes drugs raise red flag for FDA oversight

  May 28, 2020

• Venture capital found its footing in biotech. Then came the virus.

  May 26, 2020

• High expectations cast a shadow over Gilead and Galapagos' positive data

  May 21, 2020

• Little-known drug manufacturer gets big contract for COVID-19 response

  May 19, 2020

• Gilead licenses COVID-19 drug to 5 generics companies

  May 13, 2020

• GenFit delivers latest NASH drug failure

  May 11, 2020

• MyoKardia pops as heart drug passes most important test

  May 11, 2020

• After trial failure, Enanta narrows its focus to NASH

  May 7, 2020

• Novo's diabetes drug also appears to work in NASH

  May 6, 2020

• After 2 months of work, Alnylam has its top pick for a COVID-19 drug

  May 4, 2020

• Agios drops as COVID-19 takes a toll on drug studies

  May 1, 2020

• Vertex's drug launch hits new heights, but further growth could be harder to find

  April 30, 2020

• Merck starts to feel COVID-19's effects

  April 28, 2020

• Axsome, beating the odds, finds success treating Alzheimer's agitation

  April 27, 2020

• Launch for Neurocrine Parkinson's drug put on hold because of coronavirus

  April 24, 2020

• Biogen hammered with questions as Alzheimer's drug moves slower than expected

  April 22, 2020

• After 'superspreading' event, Biogen to build hub for COVID-19 patient data

  April 16, 2020

• Blackstone backs Alnylam with up to $2B investment

  April 13, 2020

• Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process

  April 7, 2020

• Alnylam and Dicerna are pals now, which could spell trouble for Arrowhead

  April 6, 2020

• Ultragenyx's gene therapy technology finds another interested party

  April 1, 2020

• A small NASH drugmaker finds positive data, but coronavirus makes for a 'tricky' path forward

  March 31, 2020

• J&J picks top coronavirus vaccine candidate; human tests to start in September

  March 30, 2020

• 5 FDA approval decisions to watch in the 2nd quarter

  March 30, 2020

• Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug

  March 25, 2020

• Novavax's positive flu data bring a stock bump and a spotlight on coronavirus vaccine

  March 24, 2020

• In hard-hit Seattle, coronavirus pushes biotechs to a new normal

  March 19, 2020

• Regeneron expects its antibody cocktail for coronavirus to enter human testing in early summer

  March 17, 2020

• Rubius scraps lead candidate as it exits rare disease drugmaking

  March 12, 2020

• Acceleron shelves drug after disappointing readout

  March 10, 2020

• Tracking biopharma's response to the new coronavirus

  March 9, 2020

• Takeda starts work on treatment for coronavirus illness

  March 4, 2020

• Gilead breaks M&A lull with $5B immuno-oncology deal

  March 2, 2020

• Biogen, Sangamo look to tackle Alzheimer's, Parkinson's through gene regulation

  Feb. 27, 2020

• Pharmacquired: Where are all the deals?

  Feb. 27, 2020

• Amid coronavirus fears, a generics giant pledges price stability

  Feb. 26, 2020

• Esperion adds more competition to cholesterol drug market

  Feb. 21, 2020

• BioMarin inches closer to a gene therapy first

  Feb. 21, 2020

• GenFit delays data readout, raising doubts about its place in NASH

  Feb. 21, 2020

• Teva's neuroscience drug falls short at the finish line

  Feb. 20, 2020

• Bluebird's gene therapy hits another delay, this time in the US

  Feb. 19, 2020

• Akebia locks down control over partner's new regulatory fast pass

  Feb. 18, 2020

• Cancer concerns knock Eisai's weight loss drug from market

  Feb. 14, 2020

• The cancer genes Wall Street is flooding with cash

  Feb. 13, 2020

• Bayer, looking to grow pharmaceutical sales, seeds new research center

  Feb. 11, 2020

• Biogen dips as Alzheimer's drugs from Lilly, Roche fail again

  Feb. 10, 2020

• Are Novartis and Regeneron seeing the same thing?

  Feb. 7, 2020

• Sanofi MS drug results set stage for extensive late-stage testing

  Feb. 6, 2020

• Biogen boosted as Mylan patent challenge fails

  Feb. 5, 2020

• Merck joins peers in spinning off lower growth drugs

  Feb. 5, 2020

• Bristol-Myers launches biotech targeting fibrosis, inflammation

  Feb. 4, 2020

• Catalent, expecting a boom in cell therapy, bids for Masthercell

  Feb. 3, 2020

• Vertex impresses with strong Trikafta launch

  Jan. 30, 2020

• German Merck continues manufacturing buildout with $275M investment

  Jan. 30, 2020

• With no Alzheimer's update, attention turns to Biogen's troubles

  Jan. 30, 2020

• Big pharma backed away from brain drugs. Is a return in sight?

  Jan. 29, 2020

• Acceleron soars on blood pressure data despite lengthy road to market

  Jan. 28, 2020

• Pfizer hits its biosimilar stride

  Jan. 27, 2020

• Ipsen pauses studies of drug for rare bone disease

  Jan. 24, 2020

• 5 biopharmas to watch as the decade's last earnings kick off

  Jan. 21, 2020

• While expected, Intercept's approval delay adds to NASH uncertainty

  Jan. 17, 2020

• Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?

  Jan. 16, 2020

• Galapagos finds a new normal at biotech's biggest dealmaking event

  Jan. 15, 2020

• Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective

  Jan. 15, 2020

• Alexion's neuro bet, Rubius' trial troubles and biotech's gene therapy milestones

  Jan. 14, 2020

• BioMarin sets gene therapy sights beyond hemophilia

  Jan. 13, 2020

• Moderna, though early in development, prepares its vaccine for market

  Jan. 9, 2020

• Lilly looms over Blueprint as the biotech files targeted cancer drug

  Jan. 8, 2020

• GSK's plan to take over the HIV drug market hasn't worked out

  Jan. 6, 2020

• 5 FDA approval decisions to watch in the 1st quarter

  Jan. 2, 2020

• Intra-Cellular approval keeps focus on FDA's neuroscience review process

  Dec. 23, 2019

• Biogen, Novartis go different ways on Ionis therapies

  Dec. 19, 2019

• Global Blood taps Syros for its next act in blood disorders

  Dec. 18, 2019

• Gilead's NASH ambitions buckle under the weight of ATLAS

  Dec. 16, 2019

• Biogen's Alzheimer's drug gets caught in Sarepta's spotlight

  Dec. 13, 2019

• Merck's ArQule buy showcases pharma appetite for targeted cancer drugs

  Dec. 9, 2019

• Biotech of the Year: Galapagos

  Dec. 9, 2019

• Readout of the Year: Aducanumab's surprise revival

  Dec. 9, 2019

• Biogen's Alzheimer's pitch yields few converts

  Dec. 7, 2019

• The clearest picture of Biogen's Alzheimer's drug is still fuzzy

  Dec. 5, 2019

• What to watch as Biogen presents its all-important Alzheimer's data

  Dec. 4, 2019

• Biogen scores a rare lupus win, lending support to its new immunology focus

  Dec. 3, 2019

• Before 2019 closes, the FDA has 3 key approval decisions to make

  Nov. 27, 2019

• 2 NASH drugmakers have wildly different Mondays

  Nov. 25, 2019

• Novartis reshapes China R&D hub to reflect rapidly evolving market

  Nov. 18, 2019

• Roche wagers $1.4B that Promedior has its next big fibrosis drug

  Nov. 15, 2019

• Merck wants to know if taking out cellular trash can treat Alzheimer's

  Nov. 13, 2019

• Reata's kidney data gets a tepid response from investors

  Nov. 12, 2019

• CF Foundation puts half a billion dollars toward drugs for all patients

  Oct. 30, 2019

• What to make of Gilead's latest NASH deal

  Oct. 28, 2019

• Pharmacquired: Eylea could be in trouble, but that doesn't make Regeneron a buyer

  Oct. 25, 2019

• Vertex clears its biggest commercial hurdle: UK insurance coverage

  Oct. 24, 2019

• In major surprise, Biogen will ask FDA to approve Alzheimer's drug aducanumab

  Oct. 22, 2019

• Vertex wins speedy approval for cystic fibrosis triplet

  Oct. 21, 2019

• GSK hands 2 of its less profitable vaccines to Bavarian Nordic

  Oct. 21, 2019

• Alexion bids for a smaller version of itself, spurring concerns about the FTC

  Oct. 16, 2019

• Reata surprises with positive data in challenging rare disease

  Oct. 15, 2019

• Five Prime's restructuring claims more jobs

  Oct. 11, 2019

• UCB bets more on rare disease drugs with Ra Pharma acquisition

  Oct. 10, 2019

• Eylea casts a shadow over Novartis' latest approval

  Oct. 8, 2019

• After more than a year, Gilead finds new chief medical officer

  Oct. 7, 2019

• Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion

  Oct. 4, 2019

• Gene therapy stocks have taken a beating. Their recovery may be slow

  Oct. 3, 2019

• Biogen's R&D head is out, following string of clinical setbacks

  Oct. 1, 2019

• Sobi finds another fit for its dealmaking strategy

  Sept. 30, 2019

• Pfizer's new JAK drug works, but class safety concerns linger

  Sept. 27, 2019

• Investors conclude there are probably better NASH drugs than Enanta's

  Sept. 26, 2019

• Alder's migraine drug attracted plenty of dealmakers. The company, not so much

  Sept. 24, 2019

• Cancer centers stretching to keep up with pharma's oncology interest

  Sept. 23, 2019

• Merck, Pfizer execs explain how they tap sites for cancer trials

  Sept. 23, 2019

• J&J finds competitive edge with latest Erleada approval

  Sept. 18, 2019

• Vertex hits a biomarker bump on road to new drug

  Sept. 17, 2019

• Opioid giant Purdue files for bankruptcy to pay for sweeping settlement

  Sept. 16, 2019

• Vertex makes headway in UK reimbursement

  Sept. 12, 2019

• Drug companies pay for exclusive access to UK genetic data

  Sept. 11, 2019

• Survey suggests Ionis is losing battle against Pfizer and Alnylam

  Sept. 10, 2019

• Celltrion taps Lonza to produce some of its Remicade biosimilar

  Sept. 5, 2019

• Pharmacquired: Vertex has an appetite for deals. Gene therapy is on the menu

  Sept. 5, 2019

• Skyrizi looks ready to soar after strong launch

  Sept. 4, 2019

• Catalent's legacy business outshined by acquisitions

  Aug. 29, 2019

• FDA issues safety warning for newer hepatitis C drugs following patient deaths

  Aug. 28, 2019

• Biopharma jobs boom in Massachusetts, though challenges still exist

  Aug. 27, 2019

• Pfizer injects $500M more into gene therapy manufacturing

  Aug. 21, 2019

• NHS coverage opens up Hemlibra to thousands more patients

  Aug. 21, 2019

• AstraZeneca diabetes drug posts more positive heart data

  Aug. 20, 2019

• Price, safety will test blockbuster billing for AbbVie's new arthritis drug

  Aug. 16, 2019

• Meet the protein responsible for nearly $100B in cancer drug deals

  Aug. 16, 2019

• Nonprofit under pressure to make new TB drug affordable

  Aug. 15, 2019

• Lilly bests J&J, with implications for AbbVie's new immunology star

  Aug. 13, 2019

• As Ebola outbreak rages, researchers find promise in Regeneron drug

  Aug. 12, 2019

• Gilead's Descovy set for PrEP approval, but not without data, access concerns

  Aug. 8, 2019

• Dupixent brings long-awaited profits to Sanofi, Regeneron partnership

  Aug. 6, 2019

• Regulators, Gilead at odds over HIV drug's use in women

  Aug. 5, 2019

• Clovis dives as investor pessimism reaches 'unprecedented levels'

  Aug. 2, 2019

• Vertex expects more, perhaps bigger M&A to come

  Aug. 1, 2019

• Teva, Endo among generics paying $70M in California pay-for-delay settlement

  July 29, 2019

• Novartis heart drug misses on potentially billion-dollar market

  July 29, 2019

• Neuroscience M&A is top of mind but a hard pill to swallow

  July 29, 2019

• European regulators back Bayer, GW drugs, but with caveats

  July 26, 2019

• Merck advancing 2-drug HIV hopeful

  July 24, 2019

• Biogen turns to eye, immune diseases to balance neuro gamble

  July 23, 2019

• 5 questions going into this week's biopharma earnings

  July 22, 2019

• Gilead, Amgen, J&J most likely to buy Otezla, Wall Street predicts

  July 18, 2019

• Kite building out manufacturing as next cell therapy inches to market

  July 16, 2019

• GSK poses challenge to rival AstraZeneca with positive PARP data

  July 15, 2019

• ICER unconvinced peanut allergy drugs are better than just avoiding the food

  July 11, 2019

• New GSK data raises threat to Gilead's star HIV drug

  July 10, 2019

• UK testing Netflix-style payments to boost antibiotics development

  July 9, 2019

• BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals

  July 8, 2019

• BioPharma Dive's 10 biggest stories of the spring

  July 3, 2019

• Once 'bodies for hire,' CROs are finding a new role as data specialists

  June 28, 2019

• Digital is bringing the change clinical trials need, DIA head says

  June 28, 2019

• Aiming for price transparency, Civica Rx hits snag with bundled payments

  June 27, 2019

• FDA officials see 'missed opportunity' with patient outcomes in clinical trials

  June 26, 2019

• Conatus hits all-time low as company explores strategic alternatives

  June 25, 2019

• Merck is on top. Investors worry there's only one way to go.

  June 21, 2019

• Catalent to buy Bristol-Myers plant to grow biologics, European business

  June 19, 2019

• Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

  June 19, 2019

• Celgene dips out of deals ahead of mega-merger

  June 17, 2019

• Despite late-stage win, investors not sold on Global Blood sickle cell drug

  June 14, 2019

• Moody's: Amgen, Biogen, Gilead have 'high capacity' to do M&A

  June 13, 2019

• Sobi restructuring business around late-stage hematology, immunology drugs

  June 12, 2019

• NASH trial miss halves CymaBay's market value

  June 11, 2019

• NASH drugmaker stocks rebound after dip on FDA guidance

  June 10, 2019

• Sanofi finds new CEO in Novartis pharma head, Brandicourt to retire

  June 7, 2019

• Fresh off being bought, Apceth preps to supply Bluebird's gene therapy

  June 6, 2019

• Biotechs dive deeper into targeted cancer research, despite costs

  June 5, 2019

• MacroGenics dives as breast cancer drug shows small improvement

  June 5, 2019

• Pfizer, late on immunotherapy, charts faster course for targeted drugs

  June 4, 2019

• Seattle Genetics drug could provide new option for bladder cancer patients

  June 3, 2019

• AstraZeneca, Merck make case for PARP's place in pancreatic cancer

  June 2, 2019

• Mitsubishi pulls EU application for ALS drug, citing 'unwarranted' data request

  May 31, 2019

• PE firm nabs Vibalogics, banking on demand for complex viral products

  May 30, 2019

• Vertex chooses its cystic fibrosis future

  May 30, 2019

• Gilead C-suite shifts again with chief commercial officer appointment

  May 29, 2019

• Teva settles for $85M in Oklahoma opioid lawsuit

  May 28, 2019

• ICER sees current DMD therapies as too pricey, but notes data limitations

  May 23, 2019

• Lilly drug scores in Phase 2 Crohn's study

  May 22, 2019

• Merck puts $1B more into oncology, with kidney cancer a focus

  May 21, 2019

• UK charity sells Keytruda rights for $1.3B

  May 20, 2019

• The NASH dash runs into some early hurdles

  May 17, 2019

• No one knows the size of the NASH market

  May 16, 2019

• On the path to patients, NASH drugs may hit a payer roadblock

  May 15, 2019

• Will a big needle burst the NASH bubble?

  May 14, 2019

• Bayer pumping $150M more into biologics

  May 13, 2019

• Takeda offloads dry eye drug to Novartis for $3.4B

  May 9, 2019

• Gilead goes after a young biotech's data to break into kidney diseases

  May 8, 2019

• Catalyst dives as FDA approves rival's rare disease drug

  May 7, 2019

• Lundbeck builds out brain drug pipeline with $250M acquisition

  May 6, 2019

• Gilead's first move under new chief is to untether Kite

  May 3, 2019

• Amid outbreaks, Merck ramps up measles vaccine manufacturing

  May 2, 2019

• Pain, cancer, immunology drugs aren't bringing the relief Lilly needs

  April 30, 2019

• Elanco trying to fetch more out of specialty veterinary drugs

  April 29, 2019

• Praluent's lower list price isn't yielding better sales yet

  April 26, 2019

• Another late-stage miss knocks Gilead from its leading NASH position

  April 25, 2019

• Biogen points to M&A power as Wall Street presses for less risky programs

  April 24, 2019

• Lilly selling antibiotic rights, manufacturing plant in China

  April 23, 2019

• Lilly bets bigger on RNA drugs, with latest deal targeting immunology

  April 22, 2019

• Sandoz takes United Therapeutics to court for 'anticompetitive' behavior

  April 18, 2019

• Gilead taps into machine learning to find new NASH drugs

  April 16, 2019

• Catalent to buy Paragon for $1.2B as gene therapy demand grows

  April 15, 2019

• Wave delays key data readout for Huntington's therapy

  April 11, 2019

• Sanofi expands insulin savings program, but affordability still an issue

  April 10, 2019

• Time to test GSK's 2-drug HIV theory

  April 9, 2019

• United Therapeutics scraps drug after late-stage miss

  April 8, 2019

• No return for the Merrimack

  April 5, 2019

• Purdue searched for new advertising agency: report

  April 3, 2019

• AveXis buys its 4th US plant in preparation of Zolgensma launch

  April 2, 2019

• Novartis bets $1.6B on a biotech's anti-inflammatory drugs

  April 1, 2019

• Bluebird gene therapy on cusp of European market entry

  March 29, 2019

• Pfizer squeezes out positive data for fructose-fighting NASH drug

  March 28, 2019

• Purdue Pharma reaches $270M deal with Oklahoma to settle opioid claims

  March 26, 2019

• Bayer, J&J to settle Xarelto claims for $775M

  March 26, 2019

• Lilly reveals Humalog pricing details amid larger scrutiny over insulin costs

  March 25, 2019

• Pharmacquired: Biogen could use a big deal. Too bad it doesn't do those

  March 22, 2019

• Biogen halts Alzheimer's drug trials in major setback for biotech

  March 21, 2019

• Pfizer makes sure it won't get left out of the gene therapy deal boom

  March 20, 2019

• Sage's postpartum depression drug is approved. Now comes the hard part

  March 19, 2019

• Dermira shares double on positive eczema data

  March 18, 2019

• Amgen not done in quest to prove Repatha

  March 15, 2019

• Sandoz CEO to depart as Novartis doubles down on biosimilars

  March 14, 2019

• Dupixent label expansion opens door to thousands more patients

  March 12, 2019

• Axovant buoyed by early gene therapy data

  March 11, 2019

• AMAG pregnancy drug's future in doubt after key study miss

  March 8, 2019

• Roche outbid competing biopharma to secure Spark deal

  March 7, 2019

• Gilead scores key HIV data as Descovy proves non-inferior to Truvada

  March 6, 2019

• 5 takeaways from Scott Gottlieb's surprising FDA departure

  March 6, 2019

• Biogen avoids heavy manufacturing lift in latest gene therapy deal

  March 5, 2019

• Biogen buys Nightstar in search of more eye gene therapies

  March 4, 2019

• AbbVie, Akcea benefit from latest CHMP recommendations

  March 1, 2019

• So far, so good for Alexion's Soliris follow-on

  Feb. 28, 2019

• Bristol-Myers hits a bump on road to Celgene takeover

  Feb. 28, 2019

• AstraZeneca's PARP drug succeeds in pancreatic cancer study

  Feb. 27, 2019

• Pharmacquired: What would a Clovis takeout look like?

  Feb. 26, 2019

• Roche acquires Spark in $4.8B gene therapy play

  Feb. 25, 2019

• Intercept stock drop reflects the high bar set for NASH drugs

  Feb. 22, 2019

• Allogene inks lease for new cell therapy manufacturing facility

  Feb. 21, 2019

• Merck takes a shot on Immune Design

  Feb. 21, 2019

• Pfizer tweaks Xeljanz trial after embolism safety signal

  Feb. 20, 2019

• CMS unveils CAR-T proposal, with emphasis on patient outcomes

  Feb. 15, 2019

• AstraZeneca retires Medimmune name amid sales turnaround

  Feb. 14, 2019

• Gilead's lead NASH drug not so STELLAR in first late-stage readout

  Feb. 12, 2019

• Eylea's PANORAMA data give fuller view of efficacy in label expansion bid

  Feb. 11, 2019

• Approving J&J's new depression drug would be an unusual move for the FDA

  Feb. 8, 2019

• J&J to disclose list prices in TV drug ads

  Feb. 7, 2019

• Tris Pharma's ibuprofen recall grows

  Feb. 7, 2019

• Mylan takes step toward knocking down key patent for Biogen's top seller

  Feb. 7, 2019

• Vertex fears its triplet will also face UK reimbursement battle

  Feb. 6, 2019

• Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron

  Feb. 6, 2019

• GSK bets billions more on oncology

  Feb. 5, 2019

• Pharma is shuffling around jobs, but a skills gap threatens the process

  Feb. 4, 2019

• Where are pharma's biggest layoffs happening?

  Feb. 4, 2019

• Does Merck need more than Keytruda?

  Feb. 1, 2019

• Novartis touts record year for manufacturing changes, but Kymriah still an overhang

  Jan. 31, 2019

• J&J's Erleada has big shoes to fill, and a tough competitor to boot

  Jan. 31, 2019

• Novartis finds stability in Cosentyx amid company shake-ups

  Jan. 30, 2019

• Biogen leaves analysts guessing on aducanumab

  Jan. 29, 2019

• Alexion's follow-on to Soliris succeeds in late-stage trial

  Jan. 28, 2019

• Wall Street can't look past AbbVie's Humira problem

  Jan. 25, 2019

• Senate Dems again targeting tax deductions for DTC drug ads

  Jan. 23, 2019

• Amid controversies, J&J voted most admired pharma

  Jan. 23, 2019

• A flashy 2019 start to pharma M&A, but will it last?

  Jan. 22, 2019

• Lilly suspends Lartruvo promotion after Phase 3 failure

  Jan. 18, 2019

• Boehringer building out biologics manufacturing in China

  Jan. 17, 2019

• Lilly rushed its Loxo deal to have a big reveal at JPM

  Jan. 17, 2019

• Aptinyx stung by pain drug's mid-stage miss

  Jan. 16, 2019

• At JPM, the NASH flood gates start to crack

  Jan. 11, 2019

• The winners and losers from JPM 2019

  Jan. 11, 2019

• J&J raises prices as Dems introduce bills aimed at lowering drug costs

  Jan. 11, 2019

• A biotech's M&A invitation and Editas' next CRISPR step

  Jan. 10, 2019

• Spark looks at scale, manufacturing as gene therapy matures

  Jan. 10, 2019

• FDA warns it won't be long before user fee funding runs dry

  Jan. 9, 2019

• Pain, depression and antipsychotic drugs drum up enthusiasm

  Jan. 8, 2019

• Sage soars on success of postpartum depression drug

  Jan. 8, 2019

• Pharmas spending too much on buybacks, not enough on big deals: report

  Jan. 7, 2019

• How Bristol-Myers' big buy could spur ripples for pharma M&A

  Jan. 4, 2019

• Seeking edge in oncology, Bristol-Myers bets big on blood cancer, cell therapies

  Jan. 3, 2019

• Eyeing NASH, Gilead wagers $1.5B on preclinical fibrosis drugs

  Dec. 19, 2018

• Vertex chalks up another win for pain drug

  Dec. 18, 2018

• Clovis dips as Tesaro reveals more details of its acquisition

  Dec. 17, 2018

• Merck shelling out $3.7B on digital solutions for animal health

  Dec. 14, 2018

• Biogen backs away from AGTC after gene therapy failure

  Dec. 13, 2018

• Lilly bets on AC Immune's tech to target Alzheimer's

  Dec. 12, 2018

• Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

  Dec. 11, 2018

• Conatus unsuccessful in spinning NASH failure

  Dec. 6, 2018

• 3 questions leaving ASH

  Dec. 5, 2018

• Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

  Dec. 5, 2018

• At ASH, bispecific cancer therapies make a mark

  Dec. 5, 2018

• ASH18: Legend's CAR-T brought back to reality

  Dec. 3, 2018

• Biotech of the Year: Spark Therapeutics

  Dec. 3, 2018

• Deal of the Year: Takeda buys Shire

  Dec. 3, 2018

• ASH18: Bluebird's follow-on CAR-T finds initial success, but durability will be key test

  Dec. 2, 2018

• Changing markets: A look at rheumatoid arthritis

  Nov. 30, 2018

• M&A trends in 2019: Will the biotech bubble burst?

  Nov. 30, 2018

• Roche joins NASH dash with Jecure buy

  Nov. 28, 2018

• Vertex's first CF triplet shows early success in late-stage trials

  Nov. 27, 2018

• 5 rheumatologists discuss the evolving landscape of RA treatment

  Nov. 26, 2018

• Drug costs pushed one-third of Americans to skip a prescription in the past year: GoodRx

  Nov. 26, 2018

• ASH data helps cement Darzalex's place in multiple myeloma standard of care

  Nov. 21, 2018

• Novartis confident in Gilenya despite FDA call out

  Nov. 21, 2018

• Sobi's late-breaking ASH data also spurs an approval

  Nov. 20, 2018

• Aimmune's peanut allergy drug draws mixed reactions

  Nov. 19, 2018

• MYSTIC deals another blow to AstraZeneca as Imfinzi misses on OS

  Nov. 16, 2018

• 3 hemophilia patients lift uniQure's value more than $450M

  Nov. 15, 2018

• 7 drugs that raised eyebrows in Q3

  Nov. 15, 2018

• Pfizer launches biosimilar version of Amgen's Epogen

  Nov. 14, 2018

• Sobi snags rights to AstraZeneca drugs in another immunology play

  Nov. 13, 2018

• AstraZeneca calls victory in CV study, but will payers feel the same?

  Nov. 12, 2018

• Gilead's search for the next great liver drug won't end with its FXR agonist

  Nov. 9, 2018

• AmerisourceBergen's compounding site still on ice despite beefed-up oversight

  Nov. 8, 2018

• PARP makers search for a way to break through

  Nov. 8, 2018

• Earnings reveal pharma's mixed feelings on Trump drug pricing proposal

  Nov. 7, 2018

• Despite Trulicity success, Lilly can't escape diabetes concerns

  Nov. 6, 2018

• Lilly strengthens Trulicity's leading position with REWIND results

  Nov. 5, 2018

• Red pill or blue? It could be a billion-dollar decision

  Oct. 29, 2018

• Endocyte deal showcases Novartis' complex manufacturing juggling act

  Oct. 25, 2018

• Biogen dips as BAN2401 data bring more questions than answers

  Oct. 25, 2018

• Amgen cuts US Repatha price 60% amid market pressure

  Oct. 24, 2018

• DTC's big issues: Trump, cancer drugs and the First Amendment

  Oct. 24, 2018

• Cryoport, in pursuit of smoother cell therapy logistics, opens new facility

  Oct. 24, 2018

• Biogen talks threats to Spinraza, but mum on BAN2401

  Oct. 23, 2018

• Lynparza hits a 'home run,' putting pressure on other PARP inhibitors

  Oct. 22, 2018

• FDA unconvinced by Novartis pitch for canakinumab

  Oct. 19, 2018

• Fresh data expands Pfizer's options for treating first-line kidney cancer

  Oct. 18, 2018

• Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices

  Oct. 17, 2018

• Amgen, Lilly migraine drugs make it onto Express Scripts' preferred list

  Oct. 17, 2018

• J&J sees 'evolution in pricing, not a revolution' in 2019

  Oct. 16, 2018

• 7 drugmakers to watch on Q3 earnings

  Oct. 15, 2018

• With latest deal, AbbVie keeps another Humira biosimilar at bay

  Oct. 11, 2018

• Regulators wary of how McKesson handles illegitimate drugs

  Oct. 11, 2018

• FDA clears Vertex, CRISPR to test gene-editing therapy in sickle cell patients

  Oct. 10, 2018

• Roche, Ionis focusing on eye disease through new deal

  Oct. 10, 2018

• Perrigo appoints new CEO, reshuffling leadership for 3rd time since 2016

  Oct. 9, 2018

• Approval puts Bausch step closer to dermatology turnaround

  Oct. 8, 2018

• Roche looks to wider market for Hemlibra with key approval

  Oct. 4, 2018

• J&J bets billions on RNA interference

  Oct. 4, 2018

• Hemophilia pressures have Bayer laying off 227 at California plant

  Oct. 3, 2018

• Paratek eyes 800 key hospital accounts for new antibiotic's rollout

  Oct. 3, 2018

• Aduro loses valuable partner as J&J exits licensing deals

  Oct. 2, 2018

• Akorn falls after judge rules Fresenius can exit takeover

  Oct. 1, 2018

• What you need to know about continuous manufacturing

  Oct. 1, 2018

• In a September full of pharma layoffs, Novo adds 250 more

  Sept. 28, 2018

• Novartis taps Cellular Biomedicines to supply Kymriah in China

  Sept. 27, 2018

• GW Pharma clears last big hurdle for cannabis-based Epidiolex with DEA rescheduling

  Sept. 27, 2018

• Pharma advertising in 2018: TV, midterms and specialty drugs

  Sept. 26, 2018

• Aldeyra has positive dry eye data — for now

  Sept. 26, 2018

• Takeda's dream of a first-line ALK inhibitor supported by late-stage data

  Sept. 25, 2018

• Gilead creates subsidiary to sell generic versions of hep C blockbusters

  Sept. 24, 2018

• J&J still has much to explore with continuous manufacturing

  Sept. 24, 2018

• For CDMOs, continuous manufacturing isn't an 'if,' but a 'how'

  Sept. 24, 2018

• Sarepta clears up clinical hold for gene therapy

  Sept. 24, 2018

• Sarepta strikes out again with European regulators

  Sept. 21, 2018

• Phase 3 win underscores that Astellas is more than Xtandi

  Sept. 20, 2018

• Novo's reorganizing claims more jobs, with R&D set to lose 400

  Sept. 18, 2018

• More data bolster AstraZeneca's 3-in-1 inhaler as other assets face setbacks

  Sept. 17, 2018

• Inbrija delay poses question: How far can Acorda fall?

  Sept. 13, 2018

• FINCH-2 data bodes well for Gilead, Galapagos JAK inhibitor

  Sept. 11, 2018

• Merck's pneumonia antibiotic stacks up in pivotal study

  Sept. 11, 2018

• As EpiPen struggles, Walgreens, Kaleo ink Auvi-Q partnership

  Sept. 7, 2018

• Akcea to reduce workforce 10% following Waylivra rejection

  Sept. 6, 2018

• Health systems roll out generic manufacturing company to meet hospital needs

  Sept. 6, 2018

• Gilead, Galapagos build case for JAK inhibitor with Phase 2 win

  Sept. 6, 2018

• Generics group says branded drugmakers blocking $13B in annual savings

  Sept. 5, 2018

• With 12 more patients dosed, Bluebird reinforces strong profile for Lenti-D

  Sept. 5, 2018

• BioPharma Dive's 10 hottest stories of the summer

  Sept. 4, 2018

• Merck's virology business needs a boost. It may not get that from 2 new HIV drugs

  Aug. 31, 2018

• What you need to know about the evolving regulatory landscape

  Aug. 31, 2018

• Catalent's growth blemished by weaker Softgel performance

  Aug. 30, 2018

• Pfizer shutters DMD program following failed study

  Aug. 30, 2018

• Despite new approval, Bayer continues to face hemophilia headwinds

  Aug. 30, 2018

• In a summer of C-suite departures, a week of commercial hires

  Aug. 29, 2018

• Waylivra rejection raises questions about Ionis, Akcea ability to close

  Aug. 28, 2018

• FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?

  Aug. 27, 2018

• Novartis, Gilead CAR-T therapies approved in Europe, putting spotlight on global manufacturing

  Aug. 27, 2018

• Approval in hand, Shire's next step is to deliver on high hopes for lanadelumab

  Aug. 24, 2018

• CSL's Seqirus expects to double flu vaccine production at NC plant

  Aug. 23, 2018

• Allergan may not lose much from latest FDA rejection

  Aug. 22, 2018

• EpiPen class action lawsuit against Mylan, Pfizer to continue, judge rules

  Aug. 21, 2018

• In pursuit of new insulins, Novo may drop more than $800M on Ziylo

  Aug. 17, 2018

• Opdivo gets speedy approval in 3rd-line small cell lung cancer

  Aug. 17, 2018

• After a hiring blitz, where is Mustang's CAR-T manufacturing headed?

  Aug. 16, 2018

• Pfizer puts up $425M in flu vaccines deal

  Aug. 16, 2018

• FDA seeks go-ahead to study risk info in DTC print ads

  Aug. 15, 2018

• J&J, ViiV tout positive data for two-drug HIV therapy

  Aug. 15, 2018

• Biogen's Spinraza gets an early no-go from NICE

  Aug. 14, 2018

• Regeneron quickly clears up 12-week Eylea CRL

  Aug. 13, 2018

• Manufacturing problems leave Jazz with 'extremely limited' Erwinaze supply

  Aug. 9, 2018

• FDA adcom support puts Paratek's antibiotic closer to approval

  Aug. 9, 2018

• Regeneron eyes DTC for its top-seller

  Aug. 8, 2018

• Regenxbio dips as gene therapy platform yields mixed results

  Aug. 8, 2018

• Teva confident migraine drug will launch this year despite new manufacturing woes

  Aug. 7, 2018

• Pain Therapeutics reorganizing as abuse-deterrent opioid rejected again

  Aug. 6, 2018

• Allergan sues Pfizer over legal fees tied to opioid marketing

  Aug. 3, 2018

• Celtaxsys CF drug misses mark on lung function

  Aug. 2, 2018

• With diabetes competitive as ever, Novo launches Ozempic DTC campaign

  Aug. 1, 2018

• Otsuka's 'next-gen' cancer drug flunks its first Phase 3 study

  July 31, 2018

• Daiichi acquires another ADC drug through Glycotope licensing deal

  July 30, 2018

• Merck, Bristol top earnings, but lung cancer rivalry remains the focus

  July 27, 2018

• Celgene bets on fantastic 5 to save portfolio

  July 26, 2018

• Rice-sized form of Roche's Lucentis heads for advanced testing

  July 25, 2018

• ResTORbio rockets up on questionable data

  July 25, 2018

• Biogen wants you to know it's more than BAN2401

  July 24, 2018

• Payers, doctors weigh AI's disruptive prescribing potential

  July 23, 2018

• Agios gets to prove its marketing abilities with new approval

  July 23, 2018

• Roche bets over $1B on tech that lets patients swallow antisense drugs

  July 20, 2018

• 7 companies to watch during Q2 earnings

  July 19, 2018

• Allergan's eye drug stacks up against Lucentis, but wider market still iffy

  July 19, 2018

• AbbVie goes 3-0 in delaying Humira rivals

  July 18, 2018

• Where does J&J's new drug fit in the crowded HIV market?

  July 18, 2018

• J&J: Growth not dependent on Zytiga

  July 17, 2018

• 5 drugs to watch as biotechs report Q2

  July 16, 2018

• Advaxis clinical hold lifted, but stock not so much

  July 13, 2018

• New epilepsy data sets Zogenix up for showdown with GW

  July 12, 2018

• Dova downgraded as high price tag threatens to slow new drug's pickup

  July 11, 2018

• Otsuka drops $430M to beef up antibody drug development

  July 11, 2018

• Celgene's blood drug scores again in Phase 3

  July 10, 2018

• Axovant parades new preclinical therapy, much to investor delight

  July 9, 2018

• DIA18: CRISPR, AI, blockchain and the future of drug development

  June 28, 2018

• DIA18: How much are PRVs even worth?

  June 27, 2018

• DIA18: Value-based contracts pose more questions than answers

  June 26, 2018

• What the pharma industry needs to know about vaccines

  June 25, 2018

• Why be a vaccine company?

  June 25, 2018

• Mustang opens CAR-T manufacturing plant, with focus on lead candidates

  June 24, 2018

• Boehringer invests $268M to further build out biologics

  June 22, 2018

• Incyte preps Jakafi expansion into graft-versus-host disease

  June 21, 2018

• 3 patients add $2.5B to Sarepta's value

  June 19, 2018

• How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass

  June 19, 2018

• ObsEva's endometriosis win puts it back in investors' good graces

  June 18, 2018

• GSK touts two-drug HIV therapy, intends to file this year

  June 14, 2018

• Big pharma shows no signs of 'massive' drug price cuts

  June 13, 2018

• Eisai looking past amyloid, tau with new drug discovery center

  June 13, 2018

• Gene-editing biotechs drop as cancer concerns weigh on CRISPR

  June 11, 2018

• Vical abandons herpes vaccine after mid-stage miss

  June 11, 2018

• Novo dips on job cuts report

  June 8, 2018

• First Neulasta biosimilar headed to US market

  June 6, 2018

• ASCO18: Who were the big winners and losers?

  June 6, 2018

• ASCO18: Jounce plummets further on weak efficacy data

  June 4, 2018

• ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2

  June 3, 2018

• ASCO18: So far, so good for Loxo's gene-focused cancer therapy

  June 2, 2018

• ASCO18: Positive readout marks step forward for Bluebird's CAR-T

  June 1, 2018

• ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

  June 1, 2018

• Vertex, CRISPR gene-editing therapy hit with clinical hold

  May 31, 2018

• Half of orphan drug sales to come from cancer, Evaluate finds

  May 30, 2018

• From the ashes, Axovant proves its recruiting skills are still top-notch

  May 29, 2018

• BioMarin cleared to bring new PKU drug to market

  May 25, 2018

• Recro plummets on CRL

  May 24, 2018

• Senators call for list prices in DTC ads

  May 23, 2018

• Teva says CGRP drug could gain approval by mid-September

  May 23, 2018

• J&J, Pfizer, Merck again lead pharma in Fortune 500

  May 22, 2018

• NASH drug pipeline headed toward uncertain market

  May 21, 2018

• Hemlibra's latest HAVEN results impress

  May 21, 2018

• Amgen, Novartis' closely watched migraine drug approved

  May 18, 2018

• FDA clears new tool in fight against opioid epidemic

  May 17, 2018

• Oncology boom spurs DTC advertising, and with it controversy

  May 16, 2018

• Merck, Eiger expand drug licensing deal to include rare disease indication

  May 16, 2018

• Lilly's CGRP drug succeeds in 'worst kind of migraine'

  May 15, 2018

• Lilly drops $110M to bring cancer compound back in house

  May 14, 2018

• Adcomm support removes one hurdle for Ionis, Akcea drug, but many remain

  May 11, 2018

• IPR protocol would change under new PTO proposal

  May 10, 2018

• Lipocine's testosterone drug rejected again

  May 9, 2018

• Outlook for Ionis, Akcea drug marred by safety concerns

  May 8, 2018

• ICER: Vertex's CF drugs too expensive

  May 7, 2018

• Celgene's timeline for refiling ozanimod gets mixed reviews

  May 4, 2018

• Despite stock slump, Regeneron remains as confident as ever

  May 3, 2018

• New approval sets up CAR-T showdown for Gilead, Novartis

  May 2, 2018

• Esperion tumbles as patient deaths weigh on cholesterol drug

  May 2, 2018

• Q1 earnings preview: Novo, Celgene still to come

  May 1, 2018

• Spark sells regulatory fast pass to Jazz for $110M

  April 30, 2018

• Allergan defends ubrogepant's marketability

  April 27, 2018

• Dupixent stumbles as Sanofi muddles through tough times

  April 27, 2018

• A metabolite will make or break Celgene's ozanimod

  April 26, 2018

• Shire, tight-lipped on Takeda, focuses on portfolio's potential

  April 26, 2018

• Supreme Court upholds constitutionality of IPR

  April 25, 2018

• The pharma supply chain: What you need to know

  April 24, 2018

• Lilly's JAK woes set the stage for AbbVie, Gilead to jump ahead

  April 24, 2018

• Immunotherapies, biosimilars to dominate next week of earnings

  April 24, 2018

• Lilly's baricitinib wins FDA panel nod, but still dogged by safety issues

  April 23, 2018

• CAR-T ups challenges in pharma supply chain

  April 23, 2018

• Out-of-pocket drug costs still murky, report underscores

  April 20, 2018

• J&J reshaping its supply chain around therapies of the future

  April 19, 2018

• P&G absorbs German Merck's consumer business for $4B

  April 19, 2018

• In win for generics makers, court knocks back Maryland price gouging law

  April 18, 2018

• ImmuPharma dives on late-stage lupus failure

  April 18, 2018

• Shire's oncology exit weighs on potential Takeda bid

  April 16, 2018

• Hanmi scraps lung cancer drug due to AstraZeneca rival, reports say

  April 13, 2018

• Q1 kicks off with J&J, Novartis, Glaxo results

  April 13, 2018

• Maker of Pfizer med warned for continued testing issues

  April 12, 2018

• PCSK9s appear to be meeting less payer resistance

  April 12, 2018

• Lawmaker questions HHS drug pricing appointee for industry ties

  April 11, 2018

• Alexion broadens pipeline with $855M Wilson Therapeutics buy

  April 11, 2018

• Latest Phase 3 failure underscores Alzheimer's indomitable nature

  April 10, 2018

• Keytruda shows OS benefit across broader range of lung cancer patients

  April 9, 2018

• Clovis closes in on rival PARP drugs with latest approval

  April 6, 2018

• Medicare to pay hundreds of thousands for CAR-T therapies

  April 6, 2018

• AGC in new expansion as biologics production heats up

  April 5, 2018

• Novo charts course for sickle cell amid headwinds in hemophilia

  April 5, 2018

• NICE's first impression of Dupixent: It's not cost-effective

  April 4, 2018

• Lilly's next diabetes play would have patients implanted with engineered stem cells

  April 4, 2018

• Celgene's COO departs amid immunology setbacks

  April 3, 2018

• PhRMA argues early notice of price hikes won't benefit patients

  April 2, 2018

• Teva's 'skinny label' generic didn't cause infringement of GSK's patent, judge finds

  March 29, 2018

• Novartis sues Regeneron over manufacturing methods

  March 28, 2018

• Teva launches generic version of Shire's top-selling internal medicine

  March 28, 2018

• Takeda eyes Shire takeover

  March 28, 2018

• AnaptysBio's new allergy data has investors scratching their heads

  March 27, 2018

• Abuse deterrents still finding their niche in the pain space

  March 26, 2018

• Ablynx's anti-inflammation drug fails in lupus

  March 26, 2018

• What's more prescribed than opioids? Weirdly, a thyroid drug

  March 23, 2018

• Thermo Fisher to grow European footprint with new supply chain site

  March 22, 2018

• Sun Pharma breaks into biologics with Ilumya

  March 22, 2018

• FDA to study how drug promotion affects doctors' decisions

  March 21, 2018

• New FDA transparency push begins with J&J's Erleada

  March 20, 2018

• Drug spending growth to come solely from specialty meds, report says

  March 13, 2018

• GSK dodges another Advair copy as FDA reaffirms Hikma rejection

  March 12, 2018

• CytomX loses out on $264M as Pfizer exits deal

  March 9, 2018

• Parexel finds new CEO in INC Research vet

  March 8, 2018

• Merck KGaA's BTK drug hits in Phase 2 MS study

  March 8, 2018

• For Cosentyx, Taltz, Siliq: A marketing race to differentiate

  March 7, 2018

• Despite positive data, Esperion still has high hurdle to clear

  March 7, 2018

• 23andMe's DTC cancer test tentatively OK'd by FDA

  March 7, 2018

• Gilead builds case for switching to its new HIV triplet

  March 6, 2018

• Positive data pushes G1 to speed up development of its CDK inhibitor

  March 5, 2018

• Verona lifted as main asset shows promise in CF

  March 2, 2018

• Kodak touts study to lure pharma manufacturing

  March 1, 2018

• Portola investors are sick of AndexXa delays

  March 1, 2018

• Collegium warned for opioid drug marketing

  Feb. 28, 2018

• Hemlibra headed for Europe, eyes wider market

  Feb. 27, 2018

• Akorn tanks as puzzling probe threatens Fresenius deal

  Feb. 27, 2018

• Drug compounding oversight rises, but spotty: Pew

  Feb. 26, 2018

• The (still somewhat mysterious) science behind the microbiome

  Feb. 26, 2018

• Avonex's freefall still likely amid patent case loss

  Feb. 26, 2018

• Bristol losing its I/O talent to the likes of Pfizer, report finds

  Feb. 23, 2018

• Avid tapped to produce Enzyvant's rare disease candidate

  Feb. 22, 2018

• CDER in warning letter frenzy as pharma struggles with quality control

  Feb. 21, 2018

• Gilead wins reprieve in Merck's $2.5B patent lawsuit

  Feb. 21, 2018

• Merck buys virus maker to flesh out I/O pipeline

  Feb. 21, 2018

• AbbVie, Voyager set sights on 'one-time' Alzheimer's treatment

  Feb. 20, 2018

• Apricus plummets after ED drug rejection

  Feb. 16, 2018

• Bayer plant flagged by FDA for poor GMP practices

  Feb. 15, 2018

• Bioverativ taps new manufacturer as it steps out of Biogen's shadow

  Feb. 15, 2018

• Fresh data sets up showdown for Lilly's Taltz vs Cosentyx

  Feb. 14, 2018

• Shire's pushing its growth potential, but investors aren't sold

  Feb. 14, 2018

• New approval helps Vertex's 'cleanest growth story in biotech'

  Feb. 13, 2018

• Despite trial win, Roche's new eye drug can't escape Eylea's shadow

  Feb. 12, 2018

• SeaGen, Pieris ink deal for bispecific I/O drugs

  Feb. 9, 2018

• Isotope manufacturing headed back to US following new FDA approval

  Feb. 8, 2018

• Gilead HIV triplet wins approval, prompts GSK-backed patent lawsuit

  Feb. 8, 2018

• Pharma wades into the world of virtual reality marketing

  Feb. 7, 2018

• Biopharma in charts: Key takeaways from Q4 earnings

  Feb. 5, 2018

• Pfizer's manufacturing fix clears path for Momenta's Copaxone generic

  Feb. 1, 2018

• Vertex looks to own CF market before shifting focus

  Jan. 31, 2018

• Boehringer strikes Jardiance outcomes deal with Prime PBM

  Jan. 31, 2018

• Patient death, clinical hold sink Bellicum shares

  Jan. 31, 2018

• Sunovion Parkinson's drug scores in Phase 3

  Jan. 30, 2018

• When real-world evidence becomes a real headache

  Jan. 29, 2018

• Bioverativ investors slapped with insider trading lawsuit

  Jan. 29, 2018

• New COPD data aid AstraZeneca in uphill battle with GSK

  Jan. 26, 2018

• Pfizer's EpiPen woes creep into Canada

  Jan. 25, 2018

• Celgene's task: Turn its shiny new toys into growth drivers

  Jan. 25, 2018

• NYC seeks $500M in suit aimed at opioid manufacturers

  Jan. 24, 2018

• J&J signals new tax laws won't change its M&A strategy

  Jan. 23, 2018

• Idera, BioCryst to merge, fortifying their position in rare disease

  Jan. 22, 2018

• FDA skewers Chinese API maker for lax quality control

  Jan. 18, 2018

• Report: Small deals aren't the answer to big pharma's woes

  Jan. 18, 2018

• Shire's latest approval won't save it from Hemlibra

  Jan. 17, 2018

• AveXis builds out SMA program with new studies

  Jan. 17, 2018

• Novartis goes 2-0 against J&J in psoriasis

  Jan. 16, 2018

• AstraZeneca's PARP inhibitor gains market edge with breast cancer approval

  Jan. 12, 2018

• JPM18: Teva cutting up to 25 manufacturing sites within 2 years

  Jan. 11, 2018

• JPM18: Novavax investors cheer RSV vaccine update, then pull back

  Jan. 11, 2018

• Drug charity group bites back at HHS

  Jan. 10, 2018

• FDA slaps down Amneal bid to stop Forteo generics

  Jan. 10, 2018

• Teva, Alder ink migraine deal to avoid legal headache

  Jan. 9, 2018

• JPM18: Shire holds onto neuroscience unit, for now

  Jan. 8, 2018

• Novo Nordisk puts $3B on the table for Ablynx

  Jan. 8, 2018

• CNS drugs take center stage: BioPharma's 2018 predictions

  Jan. 8, 2018

• Taxes, tech and China to fuel pharma M&A in 2018, says EY

  Jan. 7, 2018

• With TiGenix buy and Denali deal, Takeda shows its hand

  Jan. 5, 2018

• Fresnius Kabi's investigations aren't up to snuff, says FDA

  Jan. 4, 2018

• Pfizer targets harmful proteins in $830M deal

  Jan. 4, 2018

• Big drugmakers ring in new year with price hikes

  Jan. 3, 2018

• Galapagos' progress won't rattle CF markets, analysts say

  Jan. 3, 2018

• AstraZeneca sells US rights to 4 non-core drugs

  Jan. 2, 2018

• Roche drops $1.7B for Ignyta and its lung cancer drug

  Dec. 22, 2017

• Biopharma trends to watch in 2018

  Dec. 22, 2017

• Fujifilm invests in gene therapy startup

  Dec. 21, 2017

• MilliporeSigma tapped by bluebird for manufacturing

  Dec. 21, 2017

• Biogen's Alzheimer's drug fails, putting focus all on aducanumab

  Dec. 21, 2017

• Biogen, Ionis looking for new SMA drugs following Spinraza's success

  Dec. 20, 2017

• Spending on prescription drugs has almost doubled since the '90s, report finds

  Dec. 19, 2017

• Shire's new Elaprase formulation fails late-stage trial

  Dec. 19, 2017

• Biotech IPOs show no signs of slowing down in 2018

  Dec. 18, 2017

• Shire looks to stall Hemlibra impact with court injunction

  Dec. 18, 2017

• Alnylam, Sanofi given the all-clear to resume fitusiran trials

  Dec. 15, 2017

• Abzena tapped for preclinical ADC development

  Dec. 14, 2017

• Teva to eliminate 14,000 positions in sweeping company overhaul

  Dec. 14, 2017

• Vertex licenses its first drug from CRISPR collaboration

  Dec. 13, 2017

• After a decade of work, Otsuka and GW part ways on Sativex

  Dec. 13, 2017

• Sanofi's Humalog follow-on gets FDA nod

  Dec. 12, 2017

• Pfizer's PARP inhibitor showcases efficacy in late-stage trial

  Dec. 8, 2017

• FDA lays groundwork for regulating 3D-printed drugs

  Dec. 7, 2017

• Lilly's Taltz gains new indication, improving position versus Cosentyx

  Dec. 6, 2017

• J&J, Lilly, Merck have best management in pharma, says report

  Dec. 6, 2017

• J&J, Sanofi ranked best for clinical trial transparency

  Dec. 5, 2017

• J&J jumps in on Actelion spinout's hypertension drug

  Dec. 4, 2017

• Biotech of the Year: Vertex Pharmaceuticals

  Dec. 4, 2017

• Disruption of the Year: Long-Acting Hemophilia Drugs

  Dec. 4, 2017

• The BioPharma Dive Awards for 2017

  Dec. 4, 2017

• Cali to Massachusetts: We're the better biotech hub

  Dec. 1, 2017

• Merck unveils big plans for new UK HQ

  Nov. 30, 2017

• Bayer decides it's time to stick research and development together

  Nov. 30, 2017

• FDA's generics goals may spell trouble for branded drug-device combos

  Nov. 29, 2017

• Medicines Co. sells infectious disease unit to put more money into PCSK9 drug

  Nov. 29, 2017

• AstraZeneca outlicenses Brilinta reversal agent

  Nov. 28, 2017

• How Anthem's new PBM will impact pharma

  Nov. 28, 2017

• Regeneron scraps another Eylea combo

  Nov. 27, 2017

• AmerisourceBergen hands over another $625M for manufacturing violations

  Nov. 22, 2017

• FDA pushes for more abuse-deterrent opioid generics

  Nov. 21, 2017

• Ardelyx scraps late-stage drug in another pipeline setback

  Nov. 21, 2017

• Galapagos continues in Vertex's shadow

  Nov. 20, 2017

• FDA releases its blistering Lupin warning letter

  Nov. 16, 2017

• Roche's emicizumab wins US approval, threatening shake-up for hemophilia market

  Nov. 16, 2017

• Mirati reroutes resources to I/O combo, KRAS programs

  Nov. 16, 2017

• Digital Abilify pill secures first-of-its-kind FDA approval

  Nov. 14, 2017

• Argos finds silver lining for I/O candidate

  Nov. 13, 2017

• Novartis' eye drug clearly works, but edging out Eylea won't be easy

  Nov. 13, 2017

• Ocrevus, Mvasi and 8 other drugs get CHMP go-ahead

  Nov. 10, 2017

• Lupin reeling after double whammy warning letter

  Nov. 8, 2017

• Alkermes defends promotion of its opioid dependence drug

  Nov. 8, 2017

• Ohio voters knock down drug pricing initiative

  Nov. 8, 2017

• Takeda pursuing needle-free delivery for its top-selling biologic

  Nov. 8, 2017

• Endo faces more Opana backlash, this time with Kentucky lawsuit

  Nov. 7, 2017

• Valeant hands Sprout back to former owners

  Nov. 6, 2017

• Mallinckrodt continues pipeline revamp with Ocera buy

  Nov. 3, 2017

• Shire moves Cinryze production in-house as manufacturing problems persist

  Nov. 2, 2017

• Boehringer's NASH dash gets a boost from Dicerna

  Nov. 2, 2017

• MSF inks deals for lower-cost hep C treatments

  Nov. 1, 2017

• Allergan draws up battle plans as Restasis, other drugs face patent expiries

  Nov. 1, 2017

• Sanofi passes on Parkinson's option, crushing Voyager's shares

  Oct. 31, 2017

• Barriers remain for a drug industry ready to blossom in Brazil

  Oct. 30, 2017

• AstraZeneca hands Mereo rights to lung drug

  Oct. 30, 2017

• AbbVie's anti-inflammatories key to growth

  Oct. 27, 2017

• What to expect from the rest of pharma's earnings

  Oct. 26, 2017

• Recipharm's serialization push continues with Lisbon facility

  Oct. 26, 2017

• Slow Otezla growth dampens Celgene's long-term prospects

  Oct. 26, 2017

• AbbVie taps Alector for deeper dive into Alzheimer's

  Oct. 25, 2017

• Expanded label opens new market for Alexion's Soliris

  Oct. 24, 2017

• Biogen doubling down on aducanumab

  Oct. 24, 2017

• US Spinraza sales cause concern among Biogen investors

  Oct. 24, 2017

• Global Blood abandons IPF indication after multiple trial letdowns

  Oct. 23, 2017

• What's next for biopharma Q3 earnings

  Oct. 20, 2017

• Celgene calls it quits on expensive Crohn's drug

  Oct. 20, 2017

• With generics market calling, Cambrex outfits Milan facility

  Oct. 19, 2017

• Scangos' new biotech tackling infectious disease

  Oct. 19, 2017

• Anthem leaves Express Scripts behind to roll out its own PBM

  Oct. 18, 2017

• Ignyta lifts off on cancer drug's best-in-class potential

  Oct. 18, 2017

• MassBio: Massachusetts edges out California as #1 biotech hub

  Oct. 17, 2017

• Roche kicks antibiotic development into Warp Drive

  Oct. 16, 2017

• Trevena cuts workforce 30% to free up cash

  Oct. 13, 2017

• What Q3 earnings will look like for 5 pharma giants

  Oct. 13, 2017

• Biocon manufacturing problems stall another one of its biosimilars

  Oct. 12, 2017

• FDA rejection blocks another AcelRx drug from US market

  Oct. 12, 2017

• Generon moving ahead with Phase 3 trial following SPA

  Oct. 11, 2017

• Express Scripts drops $3.6B for healthcare management company

  Oct. 10, 2017

• AbbVie solidifies its I/O pipeline with Turnstone deal

  Oct. 10, 2017

• Bayer, J&J pull the plug on large Xarelto study

  Oct. 9, 2017

• What keeps pharma execs up at night? Apparently a lot, says new report

  Oct. 6, 2017

• Lonza snatches Shire facility as biologics manufacturing rakes in returns

  Oct. 5, 2017

• Motif delivers more strong data on its antibiotic

  Oct. 5, 2017

• Allergan to Congress: The IPR system needs fixing

  Oct. 4, 2017

• Amgen digs deeper in I/O with CytomX deal

  Oct. 4, 2017

• RedHill reports positive Bekinda data, but investors wary

  Oct. 3, 2017

• FDA looking to clear path to market for complex generics

  Oct. 2, 2017

• Ablynx prepares path for lead drug after positive late-stage results

  Oct. 2, 2017

• Lilly's abema gets FDA OK, setting it up for blockbuster status

  Sept. 29, 2017

• AmerisourceBergen hands over $260M for a decade of illegal drug manufacturing

  Sept. 28, 2017

• AbbVie, Amgen reach a deal on Humira biosimilar

  Sept. 28, 2017

• What does venture capital look for when investing in biopharma?

  Sept. 26, 2017

• Acer jumps on 7-year-old data

  Sept. 25, 2017

• Intellipharmaceutics receives painful FDA rejection

  Sept. 25, 2017

• Allergan touts new data from failed NASH study

  Sept. 22, 2017

• Korean drugmaker used employees to test potentially harmful ointment, FDA says

  Sept. 21, 2017

• Fortune's Most Powerful Women list stresses gender gap in pharma

  Sept. 21, 2017

• Judge denies PhRMA, BIO jab at Nevada law

  Sept. 20, 2017

• Split adcomm vote leaves Pfizer's Sutent in limbo

  Sept. 19, 2017

• Teva offloads the rest of its women's health business for $1.4B

  Sept. 19, 2017

• How to optimize pharma sales forces in a changing marketplace

  Sept. 18, 2017

• Ultragenyx trying to snag Regenxbio's takeover target

  Sept. 18, 2017

• Bayer's PI3K inhibitor secures FDA approval

  Sept. 15, 2017

• Fujifilm opens new mammalian cell facility

  Sept. 14, 2017

• Bristol, Roche tap Halozyme for tech platform

  Sept. 14, 2017

• Onxeo finds a partner to progress its cancer medication

  Sept. 13, 2017

• FDA clears orphan drug backlog ahead of schedule

  Sept. 12, 2017

• Alexion cuts 20% of its workforce in latest restructuring

  Sept. 12, 2017

• Teva fills top spot with Lundbeck CEO

  Sept. 11, 2017

• J&J moves away from hep C due to rival drugmakers' cures

  Sept. 11, 2017

• Pfizer's EpiPen manufacturer warned by FDA

  Sept. 8, 2017

• NewLink surges on fresh indoximod data

  Sept. 8, 2017

• Integration a key focus of FDA's new drug review model

  Sept. 7, 2017

• Alnylam pauses clinical trials of hemophilia drug after patient death

  Sept. 7, 2017

• Mallinckrodt tumbles after judge invalidates Inomax patents

  Sept. 6, 2017

• Bioverativ and Bicycle keep rare disease deals rolling

  Sept. 6, 2017

• Acorda builds its defense against potential takeover

  Sept. 1, 2017

• FDA hits yet another Indian drugmaker with warning letter

  Aug. 31, 2017

• FDA issues second refuse-to-file letter in a week, this time to SteadyMed

  Aug. 31, 2017

• Aveo wins European approval for cancer drug, triggering milestone payment

  Aug. 30, 2017

• Otonomy stock crumbles as the company sidelines a key pipeline asset

  Aug. 30, 2017

• Celgene pays high upfront to extend deal with Forma

  Aug. 29, 2017

• Jazz, ImmunoGen partner on hematology, oncology drug development

  Aug. 29, 2017

• Boehringer gains approval for second Humira biosimilar in US

  Aug. 29, 2017

• Novo's Victoza approved for CV benefit

  Aug. 28, 2017

• Adamas Parkinson's drug gains FDA approval

  Aug. 25, 2017

• US, EU advance collaboration efforts on manufacturing

  Aug. 24, 2017

• Novo manufacturing subsidiary completes Budapest expansion

  Aug. 24, 2017

• AstraZeneca touts Brilinta CV benefit with new analysis

  Aug. 24, 2017

• Ultragenyx shelves genetic disease drug after trial failure

  Aug. 23, 2017

• Novogen irons out Phase 2 plans for brain cancer candidate

  Aug. 22, 2017

• Cardiome shaken by FDA no-go on heart drug refiling

  Aug. 22, 2017

• Mylan finalizes $465M settlement for EpiPen

  Aug. 17, 2017

• FDA flags drugmaker's testing of potentially poisonous powders

  Aug. 17, 2017

• Novo bests Lilly in diabetes trial, but will that lead to market advantage?

  Aug. 17, 2017

• Alexion bolsters Soliris patent defense

  Aug. 16, 2017

• Lexicon's diabetes drug continues to deliver in the clinic

  Aug. 15, 2017

• Take two: Portola's reversal agent secures FDA review

  Aug. 15, 2017

• 5 Trends influencing drug pricing

  Aug. 14, 2017

• GSK drops two Ionis drugs in pipeline revamp

  Aug. 11, 2017

• England starts prioritizing patients amid global hep B vaccine shortage

  Aug. 10, 2017

• Galapagos' new data is good, but how much weight does it carry?

  Aug. 10, 2017

• Opioid drugmakers may have to slash production under new DEA proposal

  Aug. 9, 2017

• Melinta grows pipeline through reverse merger with Cempra

  Aug. 9, 2017

• Esperion hits a homer with new cholesterol data

  Aug. 8, 2017

• Placebo response dulls otherwise shiny results for Gemphire drug

  Aug. 7, 2017

• Dynavax dips as its hep B drug faces another setback

  Aug. 4, 2017

• Closing Claris deal, Baxter set to invest in three new plants

  Aug. 3, 2017

• So far, so good for Spark in hemophilia A

  Aug. 3, 2017

• As Roche wades biosimilar waters, more competitors circle Herceptin

  Aug. 2, 2017

• 23andMe, Lundbeck unveil mega investigation of genetics' role in depression

  Aug. 2, 2017

• Idhifa approval furthers Celgene's diversification goals

  Aug. 1, 2017

• Puma's early Nerlynx launch raises doubts of a takeover

  Aug. 1, 2017

• Bristol-Myers, Clovis ink industry's latest PARP deal

  Aug. 1, 2017

• LabCorp strengthens its CRO standing with $1.2B Chiltern acquisition

  July 31, 2017

• Alexion leaves Moderna, others behind in R&D shake-up

  July 28, 2017

• Tesaro lands licensing, supply agreements for Zejula

  July 27, 2017

• Pharma buoys Bayer, but US market presents a problem

  July 27, 2017

• Quark wins in Phase 2, raising the stakes for RNAi

  July 27, 2017

• GSK gets go-ahead for new Benlysta formulation

  July 26, 2017

• Celgene pays $280M to make fraud allegations go away

  July 26, 2017

• J&J reports positive results for HIV regimen

  July 25, 2017

• Lilly, Incyte likely won't resubmit baricitinib until 2019

  July 25, 2017

• Keytruda failure another setback for PD-1/L1 class

  July 25, 2017

• Mitsubishi Tanabe to acquire NeuroDerm for $1.1B

  July 24, 2017

• 5 orphan drugs receive EMA thumbs-up

  July 21, 2017

• May day: Amgen, Novartis lock down lead for CGRP

  July 21, 2017

• GSK to ax hundreds of jobs through manufacturing shuffle

  July 20, 2017

• Ironwood touts positive data, but investors aren't sold

  July 20, 2017

• BiondVax grows vaccine production with new facility

  July 19, 2017

• PhRMA finally talks drug pricing in new campaign

  July 19, 2017

• Positive triple combo data sets up Vertex for big growth

  July 19, 2017

• Sarepta, BioMarin iron out Exondys 51 patent terms

  July 18, 2017

• J&J: Remicade holding up better than expected

  July 18, 2017

• New data from Alzheon shows long-term benefit for Alzheimer's

  July 17, 2017

• What do we know about the amyloid theory for Alzheimer's?

  July 17, 2017

• Clinical hold still in effect for Repros' oral drug

  July 17, 2017

• J&J's Tremfya approved, further crowding IL-inhibitor market

  July 14, 2017

• Vistin hands partner its opioid, CMO businesses

  July 13, 2017

• Parkinson's drug Xadago launches in US

  July 12, 2017

• Manufacturing problems once again stall Ocular's Dextenza

  July 12, 2017

• Arena pumps out positive results for hypertension drug

  July 10, 2017

• Novartis hits pause on Fovista agreement

  July 10, 2017

• Biotech IPOs more than double in Q2

  July 7, 2017

• FDA issues warning letter to Chinese heparin maker

  July 6, 2017

• Oxford BioMedica, Novartis link up on CAR-T drug production

  July 6, 2017

• Amid industry-wide pricing backlash, Vertex raises Orkambi cost

  July 5, 2017

• Kaléo launches counterclaims against Express Scripts

  July 5, 2017

• Interleukin Genetics slashes workforce, explores options

  July 5, 2017

• Alkermes needs to prove safety to succeed with 3831

  June 30, 2017

• $$$ bountiful for biotech: Atlas raises $350M in latest fund

  June 29, 2017

• Janssen gets EU nod for continuous manufacturing

  June 29, 2017

• Gemphire's cholesterol drug shows promise in Phase 2

  June 29, 2017

• FDA's first steps in drug competition plan: get more generics approved

  June 28, 2017

• Early results show promise for Ra's rare disease drug

  June 28, 2017

• Esperion locks down regulatory pathway for cholesterol combo

  June 27, 2017

• Clarus resubmits oral hormone therapy to FDA

  June 27, 2017

• Roche's could-be hemophilia blockbuster scores in clinic

  June 26, 2017

• Novartis anti-inflammatory drug locks down landmark results in CV study

  June 22, 2017

• Shire's ADHD drug secures FDA OK

  June 21, 2017

• Pricing pressures lower drug sales forecasts, new report finds

  June 21, 2017

• Novartis eyes Regeneron's blockbuster Eylea franchise

  June 20, 2017

• Safety concerns sideline Seattle Genetics' cancer candidate

  June 19, 2017

• Biotechs waded a storm in 2016, but can they stay the course?

  June 19, 2017

• EpiPen alternative Symjepi gets FDA OK

  June 16, 2017

• New deal should help Baxter speed up generic injectables development

  June 15, 2017

• Pfizer, Roche, Aspen under investigation for cancer drug pricing

  June 14, 2017

• Report: Pharma spend helps push medical costs up

  June 14, 2017

• J&J, Pfizer, Merck sit atop Fortune's 500 for pharma

  June 13, 2017

• J&J's Invokana lowers CV risk, but by enough to compete?

  June 13, 2017

• 5 Trends affecting gene therapy development

  June 12, 2017

• Regulus reports a trio of pipeline setbacks

  June 12, 2017

• Lilly preps galcanezumab for 2017 filing

  June 10, 2017

• AMRI valued at $930M in takeout offer

  June 8, 2017

• Lilly drops $55M for access to new class of diabetes drugs

  June 8, 2017

• AbbVie's JAK-1 inhibitor notches Phase 3 win in RA

  June 8, 2017

• Remodeled drug pricing bill likely to get Nevada Gov.'s signature

  June 7, 2017

• Jazz strikes positive tone for sleep drug following late-stage hits

  June 7, 2017

• ASCO17: Chi-Med, Lilly tout cancer med's efficacy in colorectal setting

  June 6, 2017

• ASCO17: J&J seeks label expansion for Zytiga

  June 5, 2017

• GSK uses priority voucher to file HIV combo

  June 2, 2017

• AbbVie, Novo, Takeda have best reputations in pharma, new study finds

  June 2, 2017

• Merck adding more than 300 new jobs to Irish manufacturing plants

  June 1, 2017

• Lilly's Strattera faces first wave of generic competition

  May 31, 2017

• Maryland Gov. allows drug price gouging bill to become law

  May 31, 2017

• NLS touts Mazindol's efficacy as it takes on ADHD market

  May 31, 2017

• J&J puts $1B on the line for success of Protagonist drug

  May 30, 2017

• Merck, UnitedHealth explore improving value-based contracts

  May 26, 2017

• FDA highlights threat bacteria poses to water-based products

  May 25, 2017

• Novartis axing 250 US positions in data operations move

  May 25, 2017

• Merck's Keytruda gets first nod in genetically-defective tumors

  May 24, 2017

• Bioverativ buys True North, and may forge ahead with more rare disease M&A

  May 23, 2017

• Investors claw for Puma shares despite questions from FDA adcomm

  May 22, 2017

• EMA recommends 11 drugs for approval in May meeting

  May 22, 2017

• Do patients understand the risk of reshaping a genome?

  May 19, 2017

• Lilly, United extend Adcirca licensing pact

  May 19, 2017

• The 'Amazon.com for scientists' just raised $24M

  May 18, 2017

• Shire's angioedema drug scores in Phase 3

  May 18, 2017

• Otsuka buys Japanese license to Teva's migraine drug

  May 17, 2017

• J&J, Abbott, Lilly lead pharma in diversity, says report

  May 16, 2017

• Synlogic goes public through merger with failed Mirna

  May 16, 2017

• Minerva's schizophrenia drug heads to late stages

  May 16, 2017

• Biogen buys stroke drug Cirara, further diversifying neuro pipeline

  May 15, 2017

• Solutions to clinical trial adherence remain elusive

  May 15, 2017

• Horizon dives into eye treatments with River Visions acquisition

  May 12, 2017

• Interim results from Capricor's ALLSTAR trial were anything but

  May 12, 2017

• InVentiv Health, INC Research merger creates top 3 CRO

  May 11, 2017

• Parexel cutting up to 1,200 jobs, moving positions to 'lower-cost locations'

  May 11, 2017

• J&J discloses DOJ investigations into marketing, advisory practices

  May 10, 2017

• AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease

  May 10, 2017

• Allergan defends threatened franchises, but says 'no large M&A'

  May 9, 2017

• Express Scripts, GoodRx roll out cost savings program

  May 8, 2017

• Novartis pushes further into pain with Durect deal

  May 8, 2017

• Bioverativ beats consensus, raising hopes it can handle looming competition

  May 4, 2017

• Dr. Reddy's manufacturing facility flagged for procedural problems

  May 4, 2017

• Payer, consumer pushback expected to dampen drug spending growth

  May 4, 2017

• Healthcare costs take center stage at LLS roundtable

  May 3, 2017

• Shire conservative as it navigates Baxalta integration

  May 3, 2017

• Late-stage failure puts an end to Aeterna Zentaris' lead therapy

  May 2, 2017

• Shire commits up to $535M for Parion's dry eye drug

  May 1, 2017

• FDA gives thumbs up to Takeda's lung cancer drug

  May 1, 2017

• Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan

  May 1, 2017

• Alexion's earnings signal a turnaround, but how will that pan out?

  April 28, 2017

• Lonza cites issues at MD plant for 'softer' Q1 performance

  April 27, 2017

• Celgene highlights MS drug in diversification push

  April 27, 2017

• Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi

  April 26, 2017

• Biogen underscores Ocrevus' threat to MS revenues

  April 25, 2017

• Biogen touts stronger-than-expected rollout for Spinraza

  April 25, 2017

• Lilly's abemaciclib hits mark in MONARCH 3

  April 24, 2017

• Q1 Earnings Preview: Novartis, Lilly, Biogen, GSK, Amgen

  April 24, 2017

• Valeant prices psoriasis drug at $42K per year

  April 21, 2017

• FDA explains why it rejected AstraZeneca's ZS-9

  April 20, 2017

• Fujifilm invests $130M in manufacturing expansions

  April 20, 2017

• AbbVie's PARP inhibitor fails two late-stage cancer trials

  April 20, 2017

• Novartis CAR-T candidate clinches breakthrough designation

  April 19, 2017

• CytRx set to file cancer drug NDA

  April 19, 2017

• Allergan, Novartis ink NASH partnership

  April 18, 2017

• OncoMed hit with another mid-stage failure

  April 17, 2017

• In more bad news, Mylan receives CRL for Indian facility

  April 13, 2017

• Biogen, Roche ink deals with Bristol for rare disease drugs

  April 13, 2017

• Biopharma IPOs sluggish in Q1. Will that continue?

  April 13, 2017

• Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes

  April 12, 2017

• Neurocrine's Ingrezza secures FDA approval

  April 12, 2017

• Maryland general assembly sends drug price gouging bill to gov.'s desk

  April 10, 2017

• OncoMed slammed by fizzled Bayer deal, Phase 2 failure

  April 10, 2017

• Clinical trial enrollment gets harder as patient populations shrink

  April 10, 2017

• Novartis licenses bite-sized biotech's dry eye drug

  April 7, 2017

• Dr. Reddy's hit with another Form 483

  April 6, 2017

• Mallinckrodt exits PhRMA before new rules take hold

  April 6, 2017

• Mallinckrodt settles investigations into suspicious opioid orders

  April 5, 2017

• RedHill acquires rights to medical food from Entera Health

  April 5, 2017

• AACR: Biden touts Moonshot success, questions Trump

  April 3, 2017

• Astellas buys Ogeda in deal worth up to $850M

  April 3, 2017

• Novartis ordered to hand over documents in kickback lawsuit

  March 31, 2017

• Novartis, Aurobindo drugs hit by EMA-advised suspensions

  March 30, 2017

• Karyopharm shakes off clinical hold for lead cancer med

  March 30, 2017

• Legwork leaves Sanofi, Regeneron confident in Dupixent uptake

  March 29, 2017

• Depomed appoints new CEO, board members at activist investor's request

  March 29, 2017

• Sanofi, Regeneron's eczema drug Dupixent gains FDA approval

  March 28, 2017

• Cempra pulls European marketing application for antibiotic

  March 28, 2017

• Allergan acne med shines in late-stage trials

  March 27, 2017

• Insys cannabinoid drug Syndros given Schedule II status

  March 24, 2017

• FDA bans Divi's Labs plant, dealing another blow to India's quality credibility

  March 23, 2017

• Ultragenyx's seizure med fails mid-stage trial

  March 23, 2017

• Life science execs increasingly interested in out-licensing

  March 22, 2017

• Novartis heart drug fails in Phase 3

  March 22, 2017

• Sanofi, Regeneron launch preemptive patent strike against Amgen

  March 21, 2017

• Daré hoping to turn Cerulean from blue to black

  March 21, 2017

• Bristol-Myers broadens CytomX partnership, spending $200M more

  March 20, 2017

• Lilly offers up drug pricing details amid ongoing scrutiny of industry

  March 20, 2017

• FDA hands AstraZeneca's ZS-9 another setback

  March 17, 2017

• Sun Pharma gets ray of good manufacturing news

  March 16, 2017

• New $300M venture firm sets sights on young biotechs

  March 16, 2017

• FDA advisory panel votes against Endo's opioid painkiller

  March 15, 2017

• Bernie Sanders calls for more broadcast news on drug pricing

  March 15, 2017

• Alexion to cut R&D, 7% of workforce

  March 14, 2017

• Investors have high expectations for cannabinoids

  March 13, 2017

• Retrophin to close Cambridge operations

  March 10, 2017

• Genentech, Novo, Regeneron make Fortune's list of best places to work

  March 9, 2017

• Beigene plans $330M biologics facility in China

  March 8, 2017

• M&A heating up among smaller I/O drugmakers

  March 8, 2017

• Amgen debuts Repatha ad amid ongoing patent battle

  March 7, 2017

• FDA lifts trial holds for Seattle Genetics' cancer med

  March 7, 2017

• PTC files DMD drug in spite of earlier rejection

  March 6, 2017

• Samsung Bioepis beats AbbVie in UK patent court

  March 6, 2017

• AstraZeneca, Sanofi partner on infant respiratory drug

  March 3, 2017

• FDA, EU amendment looks to crack down on duplicate inspections

  March 2, 2017

• Juno shelves JCAR015, shifts focus to earlier compound

  March 1, 2017

• Pfizer flagged for more manufacturing issues

  March 1, 2017

• FDA gives go-ahead to Lexicon's rare disease drug

  March 1, 2017

• Kite flying high on Zuma-1 data

  Feb. 28, 2017

• Divestitures, patent expiries loom over Valeant

  Feb. 28, 2017

• J&J unpacks pricing decisions in new transparency report

  Feb. 27, 2017

• Bristol, Roche team up with Exelixis on cancer trials

  Feb. 27, 2017

• Spectrum shareholder accuses company of 'misleading' investors

  Feb. 24, 2017

• Momenta's Copaxone generic delayed following Pfizer warning letter

  Feb. 23, 2017

• Cyclacel's lead candidate flops in Phase 3

  Feb. 23, 2017

• DMC: little promise for Argos cancer therapy

  Feb. 22, 2017

• Pfizer, Celltrion pushing for interchangeability with Inflectra

  Feb. 22, 2017

• J&J leads pharma in Fortune's most admired companies list

  Feb. 21, 2017

• Trevena stock tanks despite positive late-stage results

  Feb. 21, 2017

• Celgene notches clinical victory for its first MS drug

  Feb. 17, 2017

• Daiichi, ArQule cancer drug fails in late-stage study

  Feb. 17, 2017

• Daiichi shutters Japanese plant amid restructuring efforts

  Feb. 16, 2017

• Baxalta pushes Shire to record revenues

  Feb. 16, 2017

• Senators call on HHS' Price to fast track Canadian drug imports

  Feb. 14, 2017

• Sage forges ahead with depression drug after positive Phase 2 results

  Feb. 14, 2017

• Allergan builds out aesthetics business with $2.5B deal

  Feb. 13, 2017

• A biomarker could tackle one of worst diseases in sports

  Feb. 13, 2017

• Seattle Genetics grabs rights to Immunomedics' tumor drug

  Feb. 10, 2017

• Neurocrine enters licensing deal for Parkinson's drug

  Feb. 10, 2017

• Pfizer plans to close Australian manufacturing plant

  Feb. 9, 2017

• GSK well-positioned to weather tax changes, execs say

  Feb. 8, 2017

• Amgen secures FDA approval for hormone drug

  Feb. 8, 2017

• Allergan talks tax reform, drug pricing

  Feb. 8, 2017

• Perrigo restructures board in deal with activist investor

  Feb. 7, 2017

• Express Scripts says branded drug prices rose nearly 11% last year

  Feb. 6, 2017

• Eli Lilly plans to cut 200 R&D jobs

  Feb. 6, 2017

• Biotech IPOs off to better start in 2017

  Feb. 3, 2017

• Merck's Perlmutter: Cancer not one size fits all

  Feb. 2, 2017

• Merck unveils new Keytruda DTC ad

  Feb. 1, 2017

• Catabasis' DMD drug fails in Phase 2

  Feb. 1, 2017

• Mallinckrodt unloads spinal drug unit

  Jan. 31, 2017

• Amgen's Humira biosim clears EMA regulatory hurdle

  Jan. 30, 2017

• Humira's future remains biggest worry for AbbVie investors

  Jan. 27, 2017

• Earnings Preview: Merck set to solidify I/O lead, Sanofi still looking for deals and more

  Jan. 26, 2017

• FDA slams Jazz CMO for continued violations

  Jan. 26, 2017

• Celgene doubling down on pipeline expansion in 2017

  Jan. 26, 2017

• Payers balk at price of EpiPen rival

  Jan. 25, 2017

• Q4 was a mixed bag for pharma. Will 2017 be the same?

  Jan. 25, 2017

• Lilly turns to pain after solanezumab failure

  Jan. 25, 2017

• Merck pays $625M to settle patent battle with Bristol, Ono

  Jan. 23, 2017

• PhRMA-backed report analyzes 'complex process' of drug pricing

  Jan. 19, 2017

• Earnings preview: 7 biopharmas to watch

  Jan. 19, 2017

• Neurocrine's Tourette drug misses mark in mid-stage trial

  Jan. 19, 2017

• Evotec creates fibrotic disease company through new partnership

  Jan. 19, 2017

• Lilly acquires CoLucid, strengthening neuro pipeline

  Jan. 18, 2017

• Trial failure deals harsh blow to Alcobra

  Jan. 17, 2017

• Allergan moves toward NDA after uterine fibroid drug's success

  Jan. 17, 2017

• Daiichi closes India facility in continued R&D overhaul

  Jan. 12, 2017

• Vertex hands off cancer drugs to Merck KGaA

  Jan. 11, 2017

• Sarepta signals strong start for Exondys 51

  Jan. 11, 2017

• Kite inks China, Japan deals ahead of possible CAR-T drug approval

  Jan. 10, 2017

• Report: Oncology, profitable drugs move to market faster, patent exclusivity shrinking

  Jan. 9, 2017

• Pharma M&A may see 'banner year' in 2017, EY predicts

  Jan. 9, 2017

• JPM: Takeda acquires Ariad in $5.2B deal

  Jan. 9, 2017

• Dynavax axes staff in pivot toward I/O

  Jan. 6, 2017

• FDA releases guidance on electronic drug applications

  Jan. 5, 2017

• Halozyme unveils mid-stage data for pancreatic cancer drug

  Jan. 5, 2017

• Ocular boasts more positive data for Dextenza

  Jan. 5, 2017

• Sanofi asked to pull vaccine ads in the Philippines

  Jan. 4, 2017

• Inotek shares freefall after glaucoma drug failure

  Jan. 4, 2017

• RedHill, Concordia team up to market IBS drug

  Jan. 3, 2017

• 7 takeover targets to look out for in 2017

  Jan. 3, 2017

• A look back: Top stories of 2016

  Dec. 26, 2016

• Novartis, Sun Pharma enter deal for oncology drug Odomzo

  Dec. 23, 2016

• Sygnis puts cash to use, acquires C.B.S. Scientific

  Dec. 22, 2016

• Biotechs line up to tap growing ophthalmics market

  Dec. 21, 2016

• Novartis buttresses Alcon with Encore Vision takeover

  Dec. 21, 2016

• Novartis sells US rights to 3 COPD drugs

  Dec. 21, 2016

• FDA pushes decision on Roche MS drug to March

  Dec. 21, 2016

• Bristol continues immuno-oncology push in deal with PsiOxus

  Dec. 20, 2016

• Pfizer's Chantix loses its black box warning

  Dec. 19, 2016

• Celgene, Evotec team up on neurological treatments

  Dec. 16, 2016

• Lonza swallows Capsugel in deal worth $5.5B

  Dec. 15, 2016

• BIO President responds to QuintilesIMS pricing report

  Dec. 14, 2016

• Moody's signals bigger risks for PBMs amid pricing backlash

  Dec. 14, 2016

• Grünenthal picks up rights to pain patch from Astellas

  Dec. 13, 2016

• Centrexion osteoarthritis drug hits its mark in Phase 2

  Dec. 13, 2016

• Novartis, Ophthotech combo therapy fails in Phase 3

  Dec. 12, 2016

• AstraZeneca cuts 700 US jobs

  Dec. 9, 2016

• FDA slaps Spanish API maker with warning letter

  Dec. 8, 2016

• Endo chops sales force after ditching pain drug

  Dec. 8, 2016

• J&J, Genentech make Glassdoor's list of best places to work

  Dec. 8, 2016

• Report: Biosimilars, specialty drugs inversely impact drug spend

  Dec. 7, 2016

• AstraZeneca touts Tagrisso's edge in lung cancer

  Dec. 6, 2016

• QuintilesIMS projects slower drug spending growth through 2021

  Dec. 5, 2016

• Acetylon forms Regenacy ahead of Celgene takeover

  Dec. 5, 2016

• Roche brings Kapa into partnership with German Merck

  Dec. 2, 2016

• Report: BioMarin, Bristol, Lilly most undervalued drugmakers

  Nov. 30, 2016

• Novo Nordisk pulls ad from Breitbart

  Nov. 30, 2016

• MedImmune, Abpro link up to accelerate antibody development

  Nov. 29, 2016

• Positive trial results push Santen eye drug toward approval

  Nov. 28, 2016

• Idera sells licensing rights to shelved autoimmune drug

  Nov. 28, 2016

• Allergan builds Alzheimer's portfolio with Chase acquisition

  Nov. 23, 2016

• Walgreens expands partnership providing patient drug reviews

  Nov. 22, 2016

• Novo, Sanofi get same-day approval for diabetes drug combos

  Nov. 22, 2016

• Novartis snags sickle cell drug in Selexys acquisition

  Nov. 21, 2016

• GlobeImmune CEO steps down as partnership with Gilead fizzles

  Nov. 18, 2016

• Eagle acquires Arsia, moves in on biosimilars

  Nov. 17, 2016

• Amgen, Novartis tout top-line migraine results

  Nov. 16, 2016

• FDA issues warning to Supernus for 'misleading' marketing

  Nov. 16, 2016

• Bristol continues microbiome exploration with Enterome deal

  Nov. 16, 2016

• UniQure to cut 20% of workforce, revamp pipeline

  Nov. 15, 2016

• Novavax aims to rebound with restructuring, more trials

  Nov. 14, 2016

• Gilead's Vemlidy approved for hep B in US, EU

  Nov. 11, 2016

• RedHill full steam ahead on stomach-illness drug

  Nov. 10, 2016

• Bristol digs deeper into NASH with Nitto deal

  Nov. 10, 2016

• Kadmon cuts jobs to conserve cash, pay debt

  Nov. 9, 2016

• Endo talks pricing, generics market turmoil

  Nov. 8, 2016

• Lexicon buys Bristol neuro drug

  Nov. 8, 2016

• Cempra drug narrowly wins support of FDA panel

  Nov. 7, 2016

• Prop 61: What does it mean for drug prices?

  Nov. 4, 2016

• Troubled Infinity licenses cancer drug to Verastem

  Nov. 3, 2016

• Lonza ramps up drug manufacturing with new Swiss facility

  Nov. 3, 2016

• Cempra stock plummets after FDA raises safety concerns

  Nov. 3, 2016

• Mitsubishi strengthens arthritis portfolio with TissueGene deal

  Nov. 2, 2016

• Allergan: More M&A, international expansion

  Nov. 2, 2016

• Eisai ups investment in Alzheimer's treatments

  Oct. 31, 2016

• AbbVie upbeat on Humira as biosimilars come barreling in

  Oct. 31, 2016

• Astellas furthers oncology focus with Ganymed buy

  Oct. 28, 2016

• Witch's brew? What drugs contain leech and lizard parts

  Oct. 28, 2016

• Lilly, GSK, Gilead outsourced the most in Q3: report

  Oct. 27, 2016

• Evotec picks up CRO Cyprotex for $68M

  Oct. 27, 2016

• Bayer aims to cut costs ahead of Monsanto deal

  Oct. 26, 2016

• FDA taking a closer look at DTC animation

  Oct. 26, 2016

• Biogen quiet on new CEO, but signals optimism in Alzheimer's

  Oct. 26, 2016

• Teva clears submission hurdle for Huntington's drug

  Oct. 21, 2016

• VBL secures new Israeli manufacturing site

  Oct. 20, 2016

• Lilly breaks 40-year drought in 1L soft-tissue sarcoma

  Oct. 20, 2016

• 4 US pharma execs make Forbes 400 list

  Oct. 19, 2016

• J&J optimistic in spite of biosimilar threat

  Oct. 18, 2016

• Moderna taps Catalent for clinical manufacturing

  Oct. 17, 2016

• Chinese drugmaker, 3 others warned in FDA letters

  Oct. 13, 2016

• Regeneron eyes long-lasting Eylea in deal with Ocular

  Oct. 13, 2016

• Celltrion finds new partner after Pfizer exit

  Oct. 6, 2016

• Amgen inks latest high price-tag research collaboration

  Oct. 4, 2016

• 10 stories that had the industry talking in Q3

  Oct. 3, 2016

• Genentech commits $80M upfront in Hanmi licensing deal

  Sept. 29, 2016

• FDA hits pause on CEL-SCI Phase 3 trial

  Sept. 28, 2016